



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2400703 A1 2001/08/30

(21) **2 400 703**

(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2001/02/20 (87) Date publication PCT/PCT Publication Date: 2001/08/30 (85) Entrée phase nationale/National Entry: 2002/08/21 (86) N° demande PCT/PCT Application No.: US 2001/005703 (87) N° publication PCT/PCT Publication No.: 2001/062271 (30) Priorité/Priority: 2000/02/22 (09/510,738) US	(51) Cl.Int. <sup>7</sup> /Int.Cl. <sup>7</sup> A61K 38/17, A61K 48/00, C12Q 1/68, C07K 14/435, C07H 21/04, G01N 33/53 (71) Demandeur/Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, US (72) Inventeur/Inventor: O'BRIEN, TIMOTHY J., US (74) Agent: BORDEN LADNER GERVAIS LLP
---	--

(54) Titre : COMPOSITIONS ET METHODES PERMETTANT LE DEPISTAGE PRECOCE DU CANCER DE L'OVAIRE  
(54) Title: COMPOSITIONS AND METHODS FOR THE EARLY DIAGNOSIS OF OVARIAN CANCER

(57) **Abrégé/Abstract:**

The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number  
**WO 01/62271 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/17**,  
48/00, C07H 21/04, C07K 14/435, C12Q 1/68, G01N  
33/53

(21) International Application Number: PCT/US01/05703

(22) International Filing Date: 20 February 2001 (20.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/510,738 22 February 2000 (22.02.2000) US

(71) Applicant: **THE BOARD OF TRUSTEES OF THE  
UNIVERSITY OF ARKANSAS** [US/US]; 2404 North  
University Avenue, Little Rock, AR 72207-3608 (US).

(72) Inventor: **O'BRIEN, Timothy, J.**; 2610 North Pierce, Lit-  
tle Rock, AR 72207 (US).

(74) Agent: **ADLER, Benjamin, A.**; Adler & Associates, 8011  
Candle Lane, Houston, TX 77071 (US).

(81) Designated States (*national*): AL, AM, AT, AU, AZ, BA,  
BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES,  
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,  
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**  
— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THE EARLY DIAGNOSIS OF OVARIAN CANCER

(57) Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.



**WO 01/62271 A1**

## COMPOSITIONS AND METHODS FOR THE EARLY DIAGNOSIS OF OVARIAN CANCER

5

### BACKGROUND OF THE INVENTION

#### 10 Field of the Invention

Generally, the present invention relates to the fields of molecular biology and medicine. More specifically, the present invention is in the field of cancer, especially ovarian cancer diagnosis.

15

#### Background of the Invention

To date, ovarian cancer remains the number one killer of women with gynecologic malignant hyperplasia. Approximately 75% of women diagnosed with such cancers are already at an advanced stage (III and IV) of the disease at their initial diagnosis. During the past 20 years, neither diagnosis nor five year survival rates have greatly improved for these patients. This is substantially due to the high percentage of high-stage initial detections of the disease. Therefore, the challenge remains to develop new markers that improve early diagnosis and thereby reduce the percentage of high-stage initial diagnoses.

Extracellular proteases have already been implicated in the growth, spread and metastatic progression of many cancers, due

to the ability of malignant cells not only to grow *in situ*, but to dissociate from the primary tumor and to invade new surfaces. The ability to disengage from one tissue and re-engage the surface of another tissue is what provides for the morbidity and mortality  
5 associated with this disease. Therefore, extracellular proteases may be good candidates for markers of neoplastic development.

In order for malignant cells to grow, spread or metastasize, they must have the capacity to invade local host tissue, dissociate or shed from the primary tumor, and for metastasis to  
10 occur, enter and survive in the bloodstream, implant by invasion into the surface of the target organ and establish an environment conducive for new colony growth (including the induction of angiogenic and growth factors). During this progression, natural tissue barriers have to be degraded, including basement membranes  
15 and connective tissue. These barriers include collagen, laminin, proteoglycans and extracellular matrix glycoproteins, including fibronectin. Degradation of these natural barriers, both those surrounding the primary tumor and at the sites of metastatic invasion, is believed to be brought about by the action of a matrix of  
20 extracellular proteases.

Proteases have been classified into four families: serine proteases, metallo-proteases, aspartic proteases and cysteine proteases. Many proteases have been shown to be involved in the human disease process and these enzymes are targets for the  
25 development of inhibitors as new therapeutic agents. Additionally, certain individual proteases have been shown to be induced and overexpressed in a diverse group of cancers, and as such, are potential candidates for markers of early diagnosis and possible

therapeutic intervention. A group of examples are shown in Table 1.

**TABLE 1**

Known proteases expressed in various cancers

5		Gastric	Brain	Breast	
	Ovarian				
	Serine Proteases:	uPA	uPA	NES-1	NES-1
		PAI-1 PAI-1	uPA	uPA	
			tPA		PAI-2
10	Cysteine Proteases:	Cathepsin B	Cathepsin L	Cathepsin B	Cathepsin B
		Cathepsin L		Cathepsin L	Cathepsin L
	Metallo-proteases:	Matrilysin*	Matrilysin	Stromelysin-3	MMP-2
		Collagenase*	Stromelysin	MMP-8	
		Stromelysin-1*	Gelatinase B	MMP-9	
15				Gelatinase A	

uPA, Urokinase-type plasminogen activator; tPA, Tissue-type plasminogen activator; PAI-I, Plasminogen activator 0 inhibitors; PAI-2, Plasminogen activator inhibitors; NES-1, Normal epithelial cell-specific-1; MMP, Matrix P metallo-protease. \*Overexpressed in  
gastrointestinal ulcers.

Significantly, there is a good body of evidence supporting the downregulation or inhibition of individual proteases and the reduction in invasive capacity or malignancy. In work by Clark *et al.*, inhibition of *in vitro* growth of human small cell lung cancer was demonstrated using a general serine protease inhibitor. More recently, Torres-Rosedo *et al.*, [*Proc.Natl.Acad.Sci.USA*, 90,



7181-7185 (1993)] demonstrated an inhibition of hepatoma tumor cell growth using specific antisense inhibitors for the serine protease hepsin gene. Metastatic potential of melanoma cells has also been shown to be reduced in a mouse model using a synthetic inhibitor (batimastat) of metallo-proteases. Powell *et al.* [*Cancer Research*, 53, 417-422 (1993)] presented evidence to confirm that the expression of extracellular proteases in relatively non-invasive tumor cells enhances their malignant progression using a tumorigenic, but non-metastatic, prostate cell line. Specifically, enhanced metastasis was demonstrated after introducing and expressing the PUMP-1 metallo-protease gene. There is also a body of data to support the notion that expression of cell surface proteases on relatively non-metastatic cell types increases the invasive potential of such cells.

Thus, the prior art is deficient in a tumor marker useful as an indicator of early disease, particularly for ovarian cancers. The present invention fulfills this long-standing need and desire in the art.

## SUMMARY OF THE INVENTION

This invention allows for the detection of cancer, especially ovarian cancer, by screening for hepsin mRNA in tissue, which is indicative of the hepsin protease, which is shown herein to be specifically associated with the surface of 80 percent of ovarian and other tumors. Proteases are considered to be an integral part of tumor growth and metastasis, and therefore, markers indicative of

their presence or absence are useful for the diagnosis of cancer. Furthermore, the present invention is useful for treatment (*i.e.*, by inhibiting hepsin or expression of hepsin), for targeted therapy, for vaccination, etc.

5           In one embodiment of the present invention, there is provided a method of diagnosing cancer in an individual, comprising the steps of obtaining a biological sample from an individual and detecting hepsin in the sample. The presence of hepsin in the sample is indicative of the presence of carcinoma in the individual,  
10 wherein the absence of hepsin in the sample is indicative of the absence of carcinoma in the individual.

          In another embodiment of the present invention, there is provided a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating mRNA from the  
15 sample; and detecting hepsin mRNA in the sample. The presence of the hepsin mRNA in the sample is indicative of the presence of malignant hyperplasia, and the absence of the hepsin mRNA in the sample is indicative of the absence of malignant hyperplasia.

          In yet another embodiment of the present invention,  
20 there is provided a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating protein from the sample; and detecting hepsin protein in the sample. The presence of the hepsin protein in the sample is indicative of the presence of malignant hyperplasia, wherein the absence of the hepsin protein in  
25 the sample is indicative of the absence of malignant hyperplasia. This method may further comprise the step of comparing the hepsin protein to reference information, wherein the comparison provides a diagnosis of the malignant hyperplasia, or alternatively,

determines a treatment of the malignant hyperplasia.

In still yet another embodiment of the present invention, there is provided a method of inhibiting expression of hepsin in a cell, comprising the step of introducing a vector into a cell, wherein  
5 the vector comprises a hepsin gene in opposite orientation operably linked to elements necessary for expression. Expression of the vector produces hepsin antisense mRNA in the cell, which hybridizes to endogenous hepsin mRNA and thereby inhibits expression of hepsin in the cell.

10 In yet another embodiment of the present invention, there is provided a method of inhibiting a hepsin protein in a cell, comprising the step of introducing an antibody specific for a hepsin protein or a fragment thereof into a cell. Binding of the antibody inhibits the hepsin protein.

15 In another embodiment of the present invention, there is provided a method of targeted therapy to an individual, comprising the step of administering a compound to an individual, wherein the compound has a targeting moiety and a therapeutic moiety, wherein the targeting moiety is specific for hepsin.

20 In yet another embodiment of the present invention, there is provided a method of vaccinating an individual against hepsin, comprising the steps of inoculating an individual with a hepsin protein or fragment thereof, wherein the hepsin protein or fragment thereof lack hepsin protease activity. Inoculation with the  
25 hepsin protein or fragment thereof elicits an immune response in the individual, thereby vaccinating the individual against hepsin.

In still another embodiment of the present invention, there is provided an oligonucleotide having a sequence



complementary to SEQ ID No.188. Also embodied is a composition comprising the above-described oligonucleotide and a physiologically acceptable carrier therefore. Additionally embodied is a method of treating a neoplastic state in an individual in need of  
5 such treatment, comprising the step of administering to the individual an effective dose of the above-described oligonucleotide.

In another embodiment of the present invention, there is provided a method of screening for compounds that inhibit hepsin activity, comprising the steps of contacting a sample with a  
10 compound, wherein the sample comprises hepsin protein; and assaying for hepsin protease activity. A decrease in the hepsin protease activity in the presence of the compound relative to hepsin protease activity in the absence of the compound is indicative of a compound that inhibits hepsin activity.

Other and further aspects, features, and advantages of  
15 the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

## BRIEF DESCRIPTION OF THE DRAWINGS

The appended drawings have been included herein so  
25 that the above-recited features, advantages and objects of the invention will become clear and can be understood in detail. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred

embodiments of the invention and should not be considered to limit the scope of the invention.

**Figure 1** shows agarose gel comparison of PCR products derived from normal and carcinoma cDNA.

5 **Figure 2** shows Northern blot analysis of ovarian tumors using hepsin, SCCE, PUMP-1, TADG-14 and  $\beta$ -tubulin probes.

**Figure 3** shows amplification with serine protease redundant primers: histidine sense (S1) with aspartic acid antisense (AS1), using normal cDNA (Lane 1) and tumor cDNA (Lane 2); and  
10 histidine sense (S1) with serine antisense (AS2), using normal cDNA (Lane 3) and tumor cDNA (Lane 4).

**Figure 4** shows amplification with cysteine protease redundant primers. Normal (Lane 1), low malignant potential (Lane 2), serious carcinoma (Lane 3), mucinous carcinoma (Lane 4), and  
15 clear cell carcinoma (Lane 5).

**Figure 5** shows amplification with metallo-protease redundant primers. Normal (Lane 1), low malignant potential (Lane 2), serious carcinoma (Lane 3), mucinous carcinoma (Lane 4), and clear cell carcinoma (Lane 5).

20 **Figure 6** shows amplification with specific primers directed towards the serine protease, hepsin. Expression in normal (Lanes 1-3), low malignant potential tumors (Lanes 4-8), and ovarian carcinomas (Lanes 9-12).

**Figure 7** shows hepsin expression levels in normal, low  
25 malignant potential tumors, and ovarian carcinomas. S=serious, M=mucinous, LMP=low malignant potential.

**Figure 8** shows serine protease stratum corneum chymotrypsin enzyme (SCCE) expression in normal, low malignant

potential tumors, and ovarian carcinomas.

**Figure 9** shows metallo-protease PUMP-1 (MMP-7) gene expression in normal (lanes 1-2) and ovarian carcinomas tissue (Lanes 3-10).

5           **Figure 10A** shows Northern blot analysis of hepsin expression in normal ovary and ovarian carcinomas. *Lane 1*, normal ovary (case 10); *lane 2*, serous carcinoma (case 35); *lane 3*, mucinous carcinoma (case 48); *lane 4*, endometrioid carcinoma (case 51); and *lane 5*, clear cell carcinoma (case 54). In cases 35,  
10 51 and 54, more than a 10-fold increase in the hepsin 1.8 kb transcript abundance was observed. **Figure 10B** shows Northern blot analysis of hepsin in normal human fetal. **Figure 10C** shows Northern blot analysis of hepsin in adult tissues. Significant overexpression of the hepsin transcript is noted in both fetal liver  
15 and fetal kidney. Notably, hepsin overexpression is not observed in normal adult tissue. Slight expression above the background level is observed in the adult prostate.

**Figure 11A** shows hepsin expression in normal (N), mucinous (M) and serous (S) low malignant potential (LMP) tumors  
20 and carcinomas (CA).  $\beta$ -tubulin was used as an internal control. **Figure 11B** shows the ratio of hepsin: $\beta$ -tubulin expression in normal ovary, LMP tumor, and ovarian carcinoma. Hepsin mRNA expression levels were significantly elevated in LMP tumors, ( $p < 0.005$ ) and carcinomas ( $p < 0.0001$ ) compared to levels in normal  
25 ovary. All 10 cases of normal ovaries showed a relatively low level of hepsin mRNA expression.

**Figure 12A** shows northern blot analysis of mRNA expression of the SCCE gene in fetal tissue. **Figure 12B** shows

northern blot analysis of mRNA expression of the SCCE gene in ovarian tissue.

**Figure 13A** shows a comparison of quantitative PCR of SCCE cDNA from normal ovary and ovarian carcinomas. **Figure**  
5 **13B** shows a bar graph comparing the ratio of SCCE to  $\beta$ -tubulin in 10 normal and 44 ovarian carcinoma tissues.

**Figure 14** shows a comparison by quantitative PCR of normal and ovarian carcinoma expression of mRNA for protease M.

**Figure 15** shows the TADG-12 catalytic domain  
10 including an insert near the His 5'-end.

**Figure 16A** shows northern blot analysis comparing TADG-14 expression in normal and ovarian carcinoma tissues. **Figure 16B** shows preliminary quantitative PCR amplification of normal and carcinoma cDNAs using specific primers for TADG-14.

15 **Figure 17A** shows northern blot analysis of the PUMP-1 gene in human fetal tissue. **Figure 17B** shows northern blot analysis of the PUMP-1 gene in normal ovary and ovarian carcinomas.

**Figure 18A** shows a comparison of PUMP-1 expression  
20 in normal and carcinoma tissues using quantitative PCR with an internal  $\beta$ -tubulin control. **Figure 18B** shows the ratio of mRNA expression of PUMP-1 compared to the internal control  $\beta$ -tubulin in 10 normal and 44 ovarian carcinomas.

**Figure 19** shows a comparison of PCR amplified  
25 products for the hepsin, SCCE, protease M, PUMP-1 and Cathepsin L genes.



## DETAILED DESCRIPTION OF THE INVENTION

This invention identifies a hepsin protease on ovarian and other tumor cells which is characteristic of this type of cancer, and in various combinations with other proteases, is characteristic of individual tumor types. Such information can provide the basis for diagnostic tests (assays or immunohistochemistry), prognostic evaluation (depending on the display pattern) and therapeutic intervention utilizing either antibodies directed at the protease, antisense vehicles for downregulation or protease inhibitors both from established inhibition data and/or for the design of new drugs. Long-term treatment of tumor growth, invasion and metastasis has not succeeded with existing chemotherapeutic agents - most tumors become resistant to drugs after multiple cycles of chemotherapy.

A primary object of the present invention is a method for detecting the presence of malignant hyperplasia in a tissue sample. It is an advantage of the present invention that it has as a particular object the detection of cancer in ovarian tissue. The cancer is detected by analyzing a biological sample for the presence of markers to proteases that are specific indicators of certain types of cancer cells. This object may be accomplished by isolating mRNA from a sample or by detection of proteins by polyclonal or preferably monoclonal antibodies. When using mRNA detection, the method may be carried out by combining the isolated mRNA with reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers selected from the list in

Table 2 or as detailed above; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of malignant hyperplasia markers in the sample. For mRNA, the analyzing step may be accomplished  
5 using Northern Blot analysis to detect the presence of malignant hyperplasia markers in the amplification product. Northern Blot analysis is known in the art. The analysis step may be further accomplished by quantitatively detecting the presence of malignant hyperplasia marker in the amplification produce, and comparing the  
10 quantity of marker detected against a panel of expected values for known presence or absence in normal and malignant tissue derived using similar primers.

Another embodiment of the present invention are various nucleic acid sequences that are useful in the methods  
15 disclosed herein. These nucleic acid sequences are listed in Table 2. It is anticipated that these nucleic acid sequences be used in mixtures to accomplish the utility of this invention. Features of such mixtures include: SEQ ID No. 1 with SEQ ID No. 2; SEQ ID No. 1 with SEQ ID No. 3; SEQ ID No. 4 with SEQ ID No. 5; SEQ ID No. 6 with  
20 SEQ ID No. 7; SEQ ID No. 8 with SEQ ID No. 9; and SEQ ID No. 10 with SEQ ID No. 11. The skilled artisan may be able to develop other nucleic acid sequences and mixtures thereof to accomplish the benefit of this invention, but it is advantageous to have the sequences listed in Table 2 available without undue  
25 experimentation.

The present invention is directed toward a method of diagnosing cancer in an individual, comprising the steps of obtaining a biological sample from an individual; and detecting hepsin in the

sample. The presence of hepsin in the sample is indicative of the presence of cancer in the individual, wherein the absence of hepsin in the sample is indicative of the absence of cancer in the individual. Generally, detection of the hepsin is by means such as Northern  
5 blot, Western blot, PCR, dot blot, ELISA sandwich assay, radioimmunoassay, DNA array chips and flow cytometry. An example of a typical cancer diagnosed by this method is ovarian cancer.

The present invention is also directed toward a method  
10 for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating mRNA from the sample; and detecting hepsin mRNA in the sample. The presence of the hepsin mRNA in the sample is indicative of the presence of malignant hyperplasia, wherein the absence of the hepsin mRNA in the sample  
15 is indicative of the absence of malignant hyperplasia. This method may further comprise the step of comparing the hepsin mRNA to reference information, wherein the comparison provides a diagnosis and/or determines a treatment of the malignant hyperplasia. A typical means of detection of hepsin mRNA is by PCR amplification,  
20 which, preferably, uses primers shown in SEQ ID No. 8 and SEQ ID No. 9. Representative biological samples include a tissue and a bodily fluid, wherein the bodily fluid is preferably blood.

The present invention is additionally directed toward a method for detecting malignant hyperplasia in a biological sample,  
25 comprising the steps of isolating protein from the sample; and detecting hepsin protein in the sample. The presence of the hepsin protein in the sample is indicative of the presence of malignant hyperplasia, wherein the absence of the hepsin protein in the sample

is indicative of the absence of malignant hyperplasia. This method also may comprise the step of comparing the hepsin protein to reference information, wherein the comparison provides a diagnosis or determines a treatment of the malignant hyperplasia. Preferably, the detection of the hepsin protein is by immunoaffinity to an antibody which is specific for hepsin. Representative biological samples are a tissue and a bodily fluid, and it is preferable that the bodily fluid is blood.

The present invention is further directed toward a method of inhibiting expression of hepsin in a cell, comprising the step of introducing a vector into a cell, wherein the vector comprises a hepsin gene in opposite orientation operably linked to elements necessary for expression, wherein expression of the vector produces hepsin antisense mRNA in the cell. The hepsin antisense mRNA hybridizes to endogenous hepsin mRNA, thereby inhibiting expression of hepsin in the cell.

The present invention is still further directed toward a method of inhibiting a hepsin protein in a cell, comprising the step of introducing an antibody into a cell, wherein the antibody is specific for a hepsin protein or a fragment thereof. Binding of the antibody to hepsin inhibits the hepsin protein. Preferably, the hepsin fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

The present invention is also directed toward a method of targeted therapy to an individual, comprising the step of administering a compound to an individual, wherein the compound



has a targeting moiety and a therapeutic moiety, and wherein the targeting moiety is specific for hepsin. Preferably, the targeting moiety is an antibody specific for hepsin or a ligand or ligand binding domain that binds hepsin. Likewise, the therapeutic moiety is preferably a radioisotope, a toxin, a chemotherapeutic agent, an immune stimulant or cytotoxic agent. Generally, the individual suffers from a disease such as ovarian cancer, lung cancer, prostate cancer, colon cancer or another cancer in which hepsin is overexpressed.

The present invention is additionally directed toward a method of vaccinating an individual against hepsin, comprising the steps of inoculating an individual with a hepsin protein or fragment thereof, wherein the hepsin protein or fragment thereof lack hepsin protease activity. Inoculation with the hepsin protein, or fragment thereof, elicits an immune response in the individual, thereby vaccinating the individual against hepsin. Generally, this method is applicable when the individual has cancer, is suspected of having cancer or is at risk of getting cancer. Sequences of preferred hepsin proteins or fragment thereof are shown in SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

The present invention is yet directed toward a method of producing immune-activated cells directed toward hepsin, comprising the steps of exposing dendritic cells to hepsin protein or fragment thereof, which lacks hepsin protease activity. Typically, exposure to hepsin protein or fragment thereof activates the dendritic cells, thereby producing immune-activated cells directed toward hepsin. Generally, the immune-activated cells are B-cells, T-

cells and/or dendrites. Preferably, the hepsin fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 or 154. Oftentimes, the dendritic cells are isolated from an individual prior to exposure and then reintroduced into the individual subsequent to the exposure. Typically, the individual has cancer, is suspected of having cancer or is at risk of getting cancer.

The present invention is further directed toward an immunogenic composition, comprising an immunogenic fragment of hepsin protein and an appropriate adjuvant. Preferably, the fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 or 154.

The present invention is further directed toward an oligonucleotide having a sequence complementary to SEQ ID No.188 or a frgment thereof. The present invention further provides a composition comprising the above-described oligonucleotide and a physiologically acceptable carrier therefore, and a method of treating a neoplastic state in an individual in need of such treatment, comprising the step of administering to the individual an effective dose of the above-described oligonucleotide. Typically, the neoplastic state may be ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer or another cancer in which hepsin is overexpressed.

The present invention is still further directed toward a method of screening for compounds that inhibit hepsin activity,

comprising the steps of contacting a sample with a compound,  
wherein the sample comprises hepsin protein; and assaying for  
hepsin protease activity. A decrease in the hepsin protease activity  
in the presence of the compound relative to hepsin protease activity  
5 in the absence of the compound is indicative of a compound that  
inhibits hepsin activity.

The present invention is yet additionally directed toward  
a method for detecting ovarian malignant hyperplasia in a biological  
sample, comprising the steps of isolating the proteases or protease  
10 mRNA present in the biological sample; and detecting specific  
proteases or protease mRNA present in the biological sample. The  
proteases are selected from the group consisting of hepsin, protease  
M, complement factor B, SCCE, cathepsin L and PUMP-1. This  
method may further comprise the step of comparing the specific  
15 proteases or protease mRNA detected to reference information,  
wherein the comparison provides a diagnoses or determines a  
treatment of the malignant hyperplasia. Typically, the protease  
mRNA is detected by amplification of total mRNA, and the protease  
is detected with an antibody. Representative biological samples are  
20 blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor  
tissue biopsy and circulating tumor cells.

It will be apparent to one skilled in the art that various  
substitutions and modifications may be made to the invention  
disclosed herein without departing from the scope and spirit of the  
25 invention.

In accordance with the present invention there may be  
employed conventional molecular biology, microbiology, and  
recombinant DNA techniques within the skill of the art. Such

techniques are explained fully in the literature. See, *e.g.*, Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984);

5 "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. 1985); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. 1984); "Animal Cell Culture" (R.I. Freshney, ed. 1986); "Immobilized Cells And Enzymes" (IRL Press, 1986); B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein,

10 the following terms shall have the definitions set out below.

As used herein, the term "cDNA" shall refer to the DNA copy of the mRNA transcript of a gene.

As used herein, the term "derived amino acid sequence" shall mean the amino acid sequence determined by reading the

15 triplet sequence of nucleotide bases in the cDNA.

As used herein the term "screening a library" shall refer to the process of using a labeled probe to check whether, under the appropriate conditions, there is a sequence complementary to the probe present in a particular DNA library. In addition, "screening a

20 library" could be performed by PCR.

As used herein, the term "PCR" refers to the polymerase chain reaction that is the subject of U.S. Patent Nos. 4,683,195 and 4,683,202 to Mullis, as well as other improvements now known in the art.

25 The amino acid described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property of immunoglobulin-binding is retained



by the polypeptide. NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, *J Biol. Chem.*,  
5 243:3552-59 (1969), abbreviations for amino acid residues may be used.

It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-  
10 terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues.

A "replicon" is any genetic element (*e.g.*, plasmid, chromosome, virus) that functions as an autonomous unit of DNA  
15 replication *in vivo*; *i.e.*, capable of replication under its own control.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "vector" may  
20 further be defined as a replicable nucleic acid construct, *e.g.*, a plasmid or viral nucleic acid.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single-stranded form or as a double-stranded helix. This term  
25 refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (*e.g.*, restriction fragments), viruses, plasmids, and

chromosomes. The structure is discussed herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA).

5           An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked to suitable control sequences capable of effecting expression of the polypeptide in a cell. The need for such control sequences will vary depending upon the cell selected and the transformation method  
10 chosen. Generally, control sequences include a transcriptional promoter and/or enhancer, suitable mRNA ribosomal binding sites and sequences which control the termination of transcription and translation. Methods which are well known to those skilled in the art can be used to construct expression vectors containing  
15 appropriate transcriptional and translational control signals. See, for example, techniques described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual* (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being "operably linked" if the transcription control  
20 sequences effectively control transcription of the gene. Vectors of the invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are those derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, or herpes viruses. In general, expression vectors contain  
25 promoter sequences which facilitate the efficient transcription of the inserted DNA fragment and are used in connection with a specific host. The expression vector typically contains an origin of replication, promoter(s), terminator(s), as well as specific genes

which are capable of providing phenotypic selection in transformed cells. The transformed hosts can be fermented and cultured according to means known in the art to achieve optimal cell growth.

An "origin of replication" refers to those DNA sequences  
5 that participate in DNA synthesis.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are typically  
10 determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA  
15 sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for  
20 the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence  
25 is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will

be found a transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters typically  
5 contain Shine-Dalgarno ribosome-binding sequences in addition to the -10 and -35 consensus sequences.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of  
10 transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

A "signal sequence" can be included near the coding sequence. This sequence encodes a signal peptide, N-terminal to the  
15 polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and  
20 eukaryotes.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

A cell has been "transformed" by exogenous or  
25 heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may



be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome  
5 replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable  
10 of stable growth *in vitro* for many generations.

Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90% or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are  
15 substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art.  
20 See, *e.g.*, Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when  
25 the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example is a construct where the coding sequence itself is not found

in nature (*e.g.*, a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined  
5 herein.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include,  
10 for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be  
15 detected by any of the currently available counting procedures. The preferred isotope may be selected from  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$ . Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric,  
20 amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus  
25 peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

A particular assay system developed and utilized in the art is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantity of both the label after which  
5 binding studies are conducted to determine the extent to which the labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained.

An assay useful in the art is known as a "cis/trans" assay. Briefly, this assay employs two genetic constructs, one of which is  
10 typically a plasmid that continually expresses a particular receptor of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such as luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a  
15 particular receptor, one of the plasmids would be a construct that results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to the luciferase gene in which the response element to the particular receptor is inserted. If the compound under test is an agonist for  
20 the receptor, the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate transcription of the luciferase gene. The resulting chemiluminescence is then measured photometrically, and dose response curves are obtained and compared to those of known  
25 ligands. The foregoing protocol is described in detail in U.S. Patent No. 4,981,784.

As used herein, the term "host" is meant to include not only prokaryotes but also eukaryotes such as yeast, plant and

animal cells. A recombinant DNA molecule or gene which encodes a human hepsin protein of the present invention can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Especially preferred is the use of a  
5 vector containing coding sequences for the gene which encodes a human hepsin protein of the present invention for purposes of prokaryote transformation. Prokaryotic hosts may include *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. Eukaryotic hosts include yeasts such as *Pichia pastoris*, mammalian  
10 cells and insect cells.

As used herein, "substantially pure DNA" means DNA that is not part of a milieu in which the DNA naturally occurs, by virtue of separation (partial or total purification) of some or all of the molecules of that milieu, or by virtue of alteration of sequences  
15 that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (*e.g.*, a cDNA or a genomic or cDNA fragment  
20 produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, *e.g.*, a fusion protein. Also included is a recombinant DNA which includes a portion of the  
25 nucleotides listed in SEQ ID No. 188 and which encodes an alternative splice variant of hepsin.

By a "substantially pure protein" is meant a protein which has been separated from at least some of those components



which naturally accompany it. Typically, the protein is substantially pure when it is at least 60% (by weight) free from the proteins and other naturally-occurring organic molecules with which it is naturally associated in *vivo*. Preferably, the purity of the preparation (by weight) is at least 75%, more preferably at least 90%, and most preferably at least 99%. A substantially pure hepsin protein may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a hepsin polypeptide; or by chemically synthesizing the protein.

Purity can be measured by any appropriate method, *e.g.*, column chromatography, such as immunoaffinity chromatography using an antibody specific for hepsin, polyacrylamide gel electrophoresis, or HPLC analysis. A protein is substantially free of naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in *E. coli*, other prokaryotes, or any other organism in which they do not naturally occur.

The term "oligonucleotide", as used herein, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors, which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer", as used herein, refers to an oligonucleotide, whether occurring naturally (as in a purified restriction digest) or produced synthetically, and which is capable

of initiating synthesis of a strand complementary to a nucleic acid when placed under appropriate conditions, *i.e.*, in the presence of nucleotides and an inducing agent, such as a DNA polymerase, and at a suitable temperature and pH. The primer may be either single-  
5 stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, sequence and/or homology of primer and the method used. For example, in diagnostic  
10 applications, the oligonucleotide primer typically contains 15-25 or more nucleotides, depending upon the complexity of the target sequence, although it may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to particular target DNA sequences. This means  
15 that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment (*i.e.*, containing a restriction site) may be attached to the 5' end of the primer, with the  
20 remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementary with the sequence to hybridize therewith and form the template for synthesis of the  
25 extension product.

The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably

50 nucleotides, and most preferably 100 nucleotides or more (up to 100%) of the coding sequence of the nucleotides listed in SEQ ID No. 188 or the complement thereof. Such a probe is useful for detecting expression of hepsin in a cell by a method including the steps of (a) contacting mRNA obtained from the cell with a labeled hepsin hybridization probe; and (b) detecting hybridization of the probe with the mRNA.

By "high stringency" is meant DNA hybridization and wash conditions characterized by high temperature and low salt concentration, *e.g.*, wash conditions of 65°C at a salt concentration of approximately 0.1X SSC, or the functional equivalent thereof. For example, high stringency conditions may include hybridization at about 42°C in the presence of about 50% formamide; a first wash at about 65°C with about 2X SSC containing 1% SDS; followed by a second wash at about 65°C with about 0.1X SSC.

The DNA may have at least about 70% sequence identity to the coding sequence of the nucleotides listed in SEQ ID No. 188, preferably at least 75% (*e.g.*, at least 80%); and most preferably at least 90%. The identity between two sequences is a direct function of the number of matching or identical positions. When a position in both of the two sequences is occupied by the same monomeric subunit, *e.g.*, if a given position is occupied by an adenine in each of two DNA molecules, then they are identical at that position. For example, if 7 positions in a sequence 10 nucleotides in length are identical to the corresponding positions in a second 10-nucleotide sequence, then the two sequences have 70% sequence identity. The length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably



at least 75 nucleotides, and most preferably 100 nucleotides. Sequence identity is typically measured using sequence analysis software (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group (GCG), University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705).

The present invention comprises a vector comprising a DNA sequence which encodes a hepsin protein, wherein said vector is capable of replication in a host, and comprises, in operable linkage: a) an origin of replication; b) a promoter; and c) a DNA sequence coding for said hepsin protein. Preferably, the vector of the present invention contains a portion of the DNA sequence shown in SEQ ID No. 188. Vectors may be used to amplify and/or express nucleic acid encoding a hepsin protein or fragment thereof.

In addition to substantially full-length proteins, the invention also includes fragments (*e.g.*, antigenic fragments) of the hepsin protein. As used herein, "fragment," as applied to a polypeptide, will ordinarily be at least 10 residues, more typically at least 20 residues, and preferably at least 30 (*e.g.*, 50) residues in length, but less than the entire, intact sequence. Fragments of the hepsin protein can be generated by methods known to those skilled in the art, *e.g.*, by enzymatic digestion of naturally occurring or recombinant hepsin protein, by recombinant DNA techniques using an expression vector that encodes a defined fragment of hepsin, or by chemical synthesis. The ability of a candidate fragment to exhibit a characteristic of hepsin (*e.g.*, binding to an antibody specific for hepsin) can be assessed by methods described herein. Purified hepsin or antigenic fragments of hepsin can be used to generate new antibodies or to test existing antibodies (*e.g.*, as positive controls in



a diagnostic assay) by employing standard protocols known to those skilled in the art. Included in this invention is polyclonal antisera generated by using hepsin or a fragment of hepsin as the immunogen in, *e.g.*, rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this art are employed. The monoclonal antibodies generated by this procedure can be screened for the ability to identify recombinant hepsin cDNA clones, and to distinguish them from other cDNA clones.

Further included in this invention are hepsin proteins which are encoded, at least in part, by portions of SEQ ID No. 188, *e.g.*, products of alternative mRNA splicing or alternative protein processing events, or in which a section of hepsin sequence has been deleted. The fragment, or the intact hepsin polypeptide, may be covalently linked to another polypeptide, *e.g.*, one which acts as a label, a ligand or a means to increase antigenicity.

The invention also includes a polyclonal or monoclonal antibody which specifically binds to hepsin. The invention encompasses not only an intact monoclonal antibody, but also an immunologically-active antibody fragment, *e.g.*, a Fab or (Fab)<sub>2</sub> fragment; an engineered single chain Fv molecule; or a chimeric molecule, *e.g.*, an antibody which contains the binding specificity of one antibody, *e.g.*, of murine origin, and the remaining portions of another antibody, *e.g.*, of human origin.

In one embodiment, the antibody, or a fragment thereof, may be linked to a toxin or to a detectable label, *e.g.*, a radioactive label, non-radioactive isotopic label, fluorescent label, chemiluminescent label, paramagnetic label, enzyme label, or

colorimetric label. Examples of suitable toxins include diphtheria toxin, *Pseudomonas* exotoxin A, ricin, and cholera toxin. Examples of suitable enzyme labels include malate hydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, alcohol  
5 dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholinesterase, etc. Examples of suitable radioisotopic labels  
10 include  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , etc.

Paramagnetic isotopes for purposes of *in vivo* diagnosis can also be used according to the methods of this invention. There are numerous examples of elements that are useful in magnetic resonance imaging. For discussions on *in vivo* nuclear magnetic  
15 resonance imaging, see, for example, Schaefer et al., (1989) *JACC* 14, 472-480; Shreve et al., (1986) *Magn. Reson. Med.* 3, 336-340; Wolf, G. L., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 93-95; Wesbey et al., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 145-155; Runge et al., (1984) *Invest. Radiol.* 19, 408-415. Examples of  
20 suitable fluorescent labels include a fluorescein label, an isothiocyalate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an ophthaldehyde label, a fluorescamine label, etc. Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic  
25 acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, an aequorin label, etc.

Those of ordinary skill in the art will know of other

suitable labels which may be employed in accordance with the present invention. The binding of these labels to antibodies or fragments thereof can be accomplished using standard techniques commonly known and used by those of ordinary skill in the art.

5 Typical techniques are described by Kennedy et al., (1976) *Clin. Chim. Acta* 70, 1-31; and Schurs et al., (1977) *Clin. Chim. Acta* 81, 1-40. Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester  
10 method. All of these methods are incorporated by reference herein.

Also within the invention is a method of detecting hepsin protein in a biological sample, which includes the steps of contacting the sample with the labeled antibody, *e.g.*, radioactively tagged antibody specific for hepsin, and determining whether the  
15 antibody binds to a component of the sample. Antibodies to the hepsin protein can be used in an immunoassay to detect increased levels of hepsin protein expression in tissues suspected of neoplastic transformation. These same uses can be achieved with Northern blot assays and analyses.

20 As described herein, the invention provides a number of diagnostic advantages and uses. For example, the hepsin protein is useful in diagnosing cancer in different tissues since this protein is highly overexpressed in tumor cells. Antibodies (or antigen-binding fragments thereof) which bind to an epitope specific for hepsin are  
25 useful in a method of detecting hepsin protein in a biological sample for diagnosis of cancerous or neoplastic transformation. This method includes the steps of obtaining a biological sample (*e.g.*, cells, blood, plasma, tissue, etc.) from a patient suspected of having

cancer, contacting the sample with a labeled antibody (e.g., radioactively tagged antibody) specific for hepsin, and detecting the hepsin protein using standard immunoassay techniques such as an ELISA. Antibody binding to the biological sample indicates that the sample contains a component which specifically binds to an epitope within hepsin.

Likewise, a standard Northern blot assay can be used to ascertain the relative amounts of hepsin mRNA in a cell or tissue obtained from a patient suspected of having cancer, in accordance with conventional Northern hybridization techniques known to those of ordinary skill in the art. This Northern assay uses a hybridization probe, e.g., radiolabelled hepsin cDNA, either containing the full-length, single stranded DNA having a sequence complementary to SEQ ID No. 188, or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labeled by any of the many different methods known to those skilled in this art.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion:

### **EXAMPLE 1**

25

#### Amplification of serine proteases using redundant and specific primers

Only cDNA preparations deemed free of genomic DNA



were used for gene expression analysis. Redundant primers were prepared for serine proteases, metallo-proteases and cysteine protease. The primers were synthesized to consensus sequences of amino acid surrounding the catalytic triad for serine proteases, *viz.*

5 histidine ... aspartate ... and serine. The sequences of both sense (histidine & aspartate) and antisense (aspartate and serine) redundant primers are shown in Table 2.

TABLE 2

PCR Primers	5'→3'	SEQ ID No.
<u>Redundant Primers:</u>		
Serine Protease (histidine) = S1	tgggtigtiacigcigcica(ct)tg	1
5 Serine Protease (aspartic acid) = AS1	a(ag)ia(ag)igciatitcitticc	2
Serine Protease (serine) = AS11	a(ag)iggicccicci(cg)(ta)(ag)tcicc	3
Cysteine Protease – sense	ca(ag)ggica(ag)tg(ct)ggi(ta)(cg)itg(ct)tgg	4
Cysteine Protease - antisense	taicccicc(ag)tt(ag)caicc(ct)tc	5
Metallo Protease - sense	cci(ac)gitg(tc)ggi(ga)(ta)icciga	6
10 Metallo Protease - antisense	tt(ag)tgicciai(ct)tc(ag)tg	7
<u>Specific Primers:</u>		
Serine Protease (hepsin) = sense	tgtcccgatggcgagtgttt	8
Serine Protease (hepsin) = antisense	cctgttgccatagtactgc	9
Serine Protease (SCCE) = sense	agatgaatgagtacaccgtg	10
15 Serine Protease (SCCE) = antisense	ccagtaagtccttgtaaacc	11
Serine Protease (Comp B) = sense	aaggacacgagagctgtat	12
Serine Protease (Comp B) = antisense	aagtggtagttggaggaagc	13
Serine Protease (Protease M)= sense	ctgtgatccaccctgactat	20
Serine Protease (Protease M) = antisense	caggtggatgtatgcacact	21
20 Serine Protease (TADG12) = sense (Ser10-s)	gcgcactgtgtttatgagat	22
Serine Protease (TADG12) = antisense (Ser10-as)	ctctttggcttgacttgct	23
Serine Protease (TADG13) = sense	tgaggacatcattatgcac	24
Serine Protease (TADG13) = antisense	caagttttccccataattgg	25
Serine Protease (TADG14) = sense	acagtacgcctgggagacca	26
25 Serine Protease (TADG14) = antisense	ctgagacggtgcaattctgg	27
Cysteine Protease (Cath-L) = sense	attggagagagaaaggctac	14
Cysteine Protease (Cath-L) = antisense	cttgggattgtacttacagg	15
Metallo Protease (PUMP1) = sense	cttccaaagtggtcacctac	16
Metallo Protease (PUMP1) = antisense	ctagactgctaccatccgtc	17

**EXAMPLE 2**Carcinoma tissue

Several protease entities were identified and subcloned  
5 from PCR amplification of cDNA derived from serous  
cystadenocarcinomas. Therefore, the proteases described herein  
are reflective of surface activities for this type of carcinoma, the  
most common form of ovarian cancer. Applicant has also shown  
PCR amplification bands unique to the mucinous tumor type and the  
10 clear cell type of similar base pair size. About 20-25% of ovarian  
cancers are classified as either mucinous, clear cell, or  
endometrioid.

15

**EXAMPLE 3**Ligation, transformation and sequencing

To determine the identity of the PCR products, all the  
appropriate bands were ligated into Promega T-vector plasmid and  
20 the ligation product was used to transform JM109 cells (Promega)  
grown on selective media. After selection and culturing of  
individual colonies, plasmid DNA was isolated by means of the  
WIZARD MINIPREP™ DNA purification system (Promega). Inserts  
were sequenced using a Prism Ready Reaction Dydeoxy Terminators  
25 cycle sequencing kit (Applied Biosystems). Residual dye terminators  
were removed from the completed sequencing reaction using a  
CENTRISEP SPIN™ column (Princeton Separation), and samples were  
loaded into an Applied Biosystems Model 373A DNA sequencing

system. The results of subcloning and sequencing for the serine protease primers are summarized in Table 3.

**TABLE 3**

5

Serine protease candidates

	<u>Subclone</u>	<u>Primer Set</u>	<u>Gene Candidate</u>
	1	His-Ser	Hepsin
	2	His-Ser	SCCE
10	3	His-Ser	Compliment B
	4	His-Asp	Cofactor 1
	5	His-Asp	TADG-12*
	6	His-Ser	TADG-13*
	7	His-Ser	TADG-14*
15	8	His-Ser	Protease M
	9	His-Ser	TADG-15*

\*indicates novel proteases

20

**EXAMPLE 4**

Cloning and characterization

Cloning and characterization of new gene candidates was undertaken to expand the panel representative of extracellular  
 25 proteases specific for ovarian carcinoma subtypes. Sequencing of the PCR products derived from tumor cDNA confirms the potential candidacy of these genes. The three novel genes all have conserved residues within the catalytic triad sequence consistent with their



membership in the serine protease family.

Applicant compared the PCR products amplified from normal and carcinoma cDNAs using sense-histidine and antisense-aspartate as well as sense-histidine and antisense-serine. The  
5 anticipated PCR products of approximately 200 bp and 500 bp for those pairs of primers were observed (aspartate is approximately 50-70 amino acids downstream from histidine, and serine is about 100-150 amino acids toward the carboxy end from histidine).

Figure 1 shows a comparison of PCR products derived  
10 from normal and carcinoma cDNA as shown by staining in an agarose gel. Two distinct bands in Lane 2 were present in the primer pair sense-His/antisense ASP (AS1) and multiple bands of about 500 bp are noted in the carcinoma lane for the sense-His/antisense-Ser (AS2) primer pairs in Lane 4.

15

### **EXAMPLE 5**

#### Quantitative PCR

20 The mRNA overexpression of hepsin was detected and determined using quantitative PCR. Quantitative PCR was performed generally according to the method of Noonan et al. [*Proc.Natl.Acad.Sci.,USA*, 87:7160-7164 (1990)]. The following oligonucleotide primers were used:

25 hepsin:

forward 5'-TGTCCTCGATGGCGAGTGTTT-3' (SEQ ID No. 8), and

reverse 5'-CCTGTTGGCCATAGTACTGC-3' (SEQ ID No. 9);

and  $\beta$ -tubulin:

forward 5'- TGCATTGACAACGAGGC -3' (SEQ ID No. 18), and  
reverse 5'- CTGTCTTGA CATTGTTG -3' (SEQ ID No. 19).

$\beta$ -tubulin was utilized as an internal control. The predicted sizes of the amplified genes were 282 bp for hepsin and 454 bp for  $\beta$ -  
5 tubulin. The primer sequences used in this study were designed according to the cDNA sequences described by Leytus *et al.* [*Biochemistry*, 27, 1067-1074 (1988)] for hepsin, and Hall *et al.* [*Mol. Cell. Biol.*, 3, 854-862 (1983)] for  $\beta$ -tubulin. The PCR reaction mixture consisted of cDNA derived from 50 ng of mRNA converted  
10 by conventional techniques, 5 pmol of sense and antisense primers for both the hepsin gene and the  $\beta$ -tubulin gene, 200  $\mu$ mol of dNTPs, 5  $\mu$ Ci of  $\alpha$ -<sup>32</sup>PdCTP and 0.25 units of Taq DNA polymerase with reaction buffer (Promega) in a final volume of 25  $\mu$ l. The target sequences were amplified in parallel with the  $\beta$ -tubulin gene. Thirty  
15 cycles of PCR were carried out in a Thermal Cycler (Perkin-Elmer Cetus). Each cycle of PCR included 30 sec of denaturation at 95°C, 30 sec of annealing at 63°C and 30 sec of extension at 72°C. The PCR products were separated on 2% agarose gels and the radioactivity of each PCR product was determined by using a PhosphorImager™  
20 (Molecular Dynamics). Student's *t* test was used for comparison of mean values.

Experiments comparing PCR amplification in normal ovary and ovarian carcinoma suggested overexpression and/or alteration in mRNA transcript in tumor tissues. Northern blot  
25 analysis of TADG-14 confirms a transcript size of 1.4 kb and data indicate overexpression in ovarian carcinoma (Figure 2). Isolation and purification using both PCR and a specific 250 bp PCR product to screen positive plaques yielded a 1.2 kb clone of TADG-14. Other

proteases were amplified by the same method using the appropriate primers from Table 2.

5

**EXAMPLE 6**Tissue bank

A tumor tissue bank of fresh frozen tissue of ovarian carcinomas as shown in Table 4 was used for evaluation.

10 Approximately 100 normal ovaries removed for medical reasons other than malignancy were obtained from surgery and were available as controls.

TABLE 4

Ovarian cancer tissue bank

5		Total	Stage I/II	Stage III/IV	No Stage
	<u>Serous</u>				
	Malignant	166	15	140	8
	LMP	16	9	7	0
	Benign	12	0	0	12
10	<u>Mucinous</u>				
	Malignant	26	6	14	6
	LMP	28	25	3	0
	Benign	3	0	0	3
	<u>Endometrioid</u>				
15	Malignant	38	17	21	0
	LMP	2	2	0	0
	Benign	0	0	0	0
	<u>Other*</u>				
	Malignant	61	23	29	9
20	LMP	0	0	0	0
	Benign	5	0	0	5

\*Other category includes the following tumor types: Brenner's tumor, thecoma, teratoma, fibrothecoma, fibroma, granulosa cell, clear cell, germ cell, mixed mullerian, stromal, undifferentiated, and  
 25 dysgerminoma.

From the tumor bank, approximately 100 carcinomas



were evaluated encompassing most histological sub-types of ovarian carcinoma, including borderline or low-malignant potential tumors and overt carcinomas. The approach included using mRNA prepared from fresh frozen tissue (both normal and malignant) to compare  
5 expression of genes in normal, low malignant potential tumors and overt carcinomas. The cDNA prepared from polyA<sup>+</sup> mRNA was deemed to be genomic DNA-free by checking all preparations with primers that encompassed a known intron-exon splice site using both  $\beta$ -tubulin and p53 primers.

10

### **EXAMPLE 7**

#### Northern blots

15 Significant information can be obtained by examining the expression of these candidate genes by Northern blot. Analysis of normal adult multi-tissue blots offers the opportunity to identify normal tissues which may express the protease. Ultimately, if strategies for inhibition of proteases for therapeutic intervention  
20 are to be developed, it is essential to appreciate the expression of these genes in normal tissue if and when it occurs.

Significant information is expected from Northern blot analysis of fetal tissue. Genes overexpressed in carcinomas are often highly expressed in organogenesis. As indicated, the hepsin  
25 gene cloned from hepatoma cells and overexpressed in ovarian carcinoma is overtly expressed in fetal liver. Hepsin gene expression was also detected in fetal kidney, and therefore, could be a candidate for expression in renal carcinomas.

Northern panels for examining expression of genes in a multi-tissue normal adult as well as fetal tissue are commercially available (CLONTECH). Such evaluation tools are not only important to confirm the overexpression of individual transcripts in tumor  
5 versus normal tissues, but also provides the opportunity to confirm transcript size, and to determine if alternate splicing or other transcript alteration may occur in ovarian carcinoma.

## 10 EXAMPLE 8

### Northern blot analysis

Northern blot analysis was performed as follows: 10 µg of mRNA was loaded onto a 1% formaldehyde-agarose gel,  
15 electrophoresed and blotted onto a HyBond-N<sup>+</sup>™ nylon membrane (Amersham). <sup>32</sup>P-labeled cDNA probes were made using Prime-a-Gene Labeling System™ (Promega). The PCR products amplified by specific primers were used as probes. Blots were prehybridized for 30 min and then hybridized for 60 min at 68°C with <sup>32</sup>P-labeled  
20 cDNA probe in ExpressHyb™ Hybridization Solution (CLONTECH). Control hybridization to determine relative gel loading was accomplished using the β-tubulin probe.

Normal human tissues including spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood  
25 leukocyte, heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas and normal human fetal tissues; brain, lung, liver and kidney (Human Multiple Tissue Northern Blot; CLONTECH) were all examined using the same hybridization procedure.

### **EXAMPLE 9**

PCR products corresponding to serine, cysteine and metallo-proteases

5           Based on their unique expression in either low malignant potential tumors or carcinomas, PCR-amplified cDNA products were cloned and sequenced and the appropriate gene identified based upon nucleotide and amino acid sequences stored in the GCG and EST databases. Figures 3, 4 & 5 show the PCR product displays  
10 comparing normal and carcinomatous tissues using redundant primers for serine proteases (Figure 3), for cysteine proteases (Figure 4) and for metallo-proteases (Figure 5). Note the differential expression in the carcinoma tissues versus the normal tissues. The proteases were identified using redundant cDNA  
15 primers (see Table 2) directed towards conserved sequences that are associated with intrinsic enzyme activity (for serine proteases, cysteine proteases and metallo-proteases) by comparing mRNA expression in normal, low malignant potential and overt ovarian carcinoma tissues according to Sakanari *et al.* [*Biochemistry* 86,  
20 4863-4867 (1989)].

### **EXAMPLE 10**

25   Serine proteases

For the serine protease group, using the histidine domain primer sense, S1, in combination with antisense primer AS2, the following proteases were identified:

(a) Hepsin, a trypsin-like serine protease cloned from hepatoma cells shown to be a cell surface protease essential for the growth of hepatoma cells in culture and highly expressed in hepatoma tumor cells (Figure 3, Lane 4);

5 (b) Complement factor B protease (human factor IX), a protease involved in the coagulation cascade and associated with the production and accumulation of fibrin split products associated with tumor cells (Figure 3, Lane 4). Compliment factor B belongs in the family of coagulation factors X (Christmas factor). As part of  
10 the intrinsic pathway, compliment factor B catalyzes the proteolytic activation of coagulation factor X in the presence of  $\text{Ca}^{2+}$  phospholipid and factor VIIIa e5; and

(c) A stratum corneum chymotryptic enzyme (SCCE) serine protease involved in desquamation of skin cells from the  
15 human stratum corneum (Figure 3, Lane 4). SCCE is expressed in keratinocytes of the epidermis and functions to degrade the cohesive structures in the cornified layer to allow continuous skin surface shedding.

20

### **EXAMPLE 11**

#### **Cysteine proteases**

In the cysteine protease group, using redundant sense  
25 and anti-sense primers for cysteine proteases, one unique PCR product was identified by overexpression in ovarian carcinoma when compared to normal ovarian tissue (Figure 4, Lanes 3-5). Cloning and sequencing this PCR product identified a sequence of



Cathepsin L, which is a lysosomal cysteine protease whose expression and secretion is induced by malignant transformation, growth factors and tumor promoters. Many human tumors (including ovarian) express high levels of Cathepsin L. Cathepsin L cysteine  
5 protease belongs in the stromolysin family and has potent elastase and collagenase activities. Published data indicates increased levels in the serum of patients with mucinous cystadenocarcinoma of the ovary. It has not heretofore been shown to be expressed in other ovarian tumors.

10

## **EXAMPLE 12**

### **Metallo-proteases**

15 Using redundant sense and anti-sense primers for the metallo-protease group, one unique PCR product was detected in the tumor tissue which was absent in normal ovarian tissue (Figure 5, Lanes 2-5). Subcloning and sequencing this product indicates it has complete homology in the appropriate region with the so-called  
20 PUMP-1 (MMP-7) gene. This zinc-binding metallo-protease is expressed as a proenzyme with a signal sequence and is active in gelatin and collagenase digestion. PUMP-1 has also been shown to be induced and overexpressed in 9 of 10 colorectal carcinomas compared to normal colon tissue, suggesting a role for this  
25 substrate in the progression of this disease.

**EXAMPLE 13**Expression of hepsin

The expression of the serine protease hepsin gene in 8  
 5 normal, 11 low malignant potential tumors, and 14 carcinoma (both  
 mucinous and serous type) by quantitative PCR using hepsin-specific  
 primers (see Table 2) was determined (primers directed toward the  
 $\beta$ -tubulin message were used as an internal standard) (Table 5).  
 These data confirm the overexpression of the hepsin surface  
 10 protease gene in ovarian carcinoma, including both low malignant  
 potential tumors and overt carcinoma. Expression of hepsin is  
 increased over normal levels in low malignant potential tumors, and  
 high stage tumors (Stage III) of this group have higher expression of  
 hepsin when compared to low stage tumors (Stage 1) (Table 6). In  
 15 overt carcinoma, serous tumors exhibit the highest levels of hepsin  
 expression, while mucinous tumors express levels of hepsin  
 comparable with the high stage low malignant potential group  
 (Figures 6 & 7).

20

**TABLE 5**Patient Characteristics and Expression of Hepsin Gene

	<u>Case</u>	<u>Histological type<sup>a</sup></u>	<u>Stage/Grade</u>	<u>IN<sup>b</sup></u>	<u>mRNA expression of hepsin<sup>c</sup></u>
25	1	normal ovary			n
	2	normal ovary			n
	3	normal ovary			n
	4	normal ovary			n
	5	normal ovary			n

WO 01/62271

PCT/US01/05703

	6	normal ovary			n
	7	normal ovary			n
	8	normal ovary			n
	9	normal ovary			n
5	10	normal ovary			n
	11	S adenoma (LMP)	1 / 1	N	4+
	12	S adenoma (LMP)	1 / 1	NE	4+
	13	S adenoma (LMP)	1 / 1	NE	n
	14	S adenoma (LMP)	1 / 1	N	2+
10	15	S adenoma (LMP)	3 / 1	P	4+
	16	S adenoma (LMP)	3 / 1	P	4+
	17	S adenoma (LMP)	3 / 1	P	4+
	18	M adenoma (LMP)	1 / 1	NE	4+
	19	M adenoma (LMP)	1 / 1	N	n
15	20	M adenoma (LMP)	1 / 1	N	n
	21	M adenoma (LMP)	1 / 1	N	n
	22	M adenoma (LMP)	1 / 1	NE	n
	23	S carcinoma	1 / 2	N	4+
	24	S carcinoma	1 / 3	N	4+
20	25	S carcinoma	3 / 1	NE	2+
	26	S carcinoma	3 / 2	NE	4+
	27	S carcinoma	3 / 2	P	4+
	28	S carcinoma	3 / 2	NE	2+
	29	S carcinoma	3 / 3	NE	2+
25	30	S carcinoma	3 / 3	NE	4+
	31	S carcinoma	3 / 3	NE	4+
	32	S carcinoma	3 / 3	NE	4+
	33	S carcinoma	3 / 3	N	4+

	34	S carcinoma	3 / 3	NE	n
	35	S carcinoma	3 / 3	NE	4+
	36	S carcinoma	3 / 3	NE	4+
	37	S carcinoma	3 / 3	NE	4+
5	38	S carcinoma	3 / 3	N	4+
	39	S carcinoma	3 / 2	NE	2+
	40	S carcinoma	3 / 3	NE	4+
	41	S carcinoma	3 / 2	NE	4+
	42	M carcinoma	1 / 2	N	n
10	43	M carcinoma	2 / 2	NE	4+
	44	M carcinoma	2 / 2	N	4+
	45	M carcinoma	3 / 1	NE	n
	46	M carcinoma	3 / 2	NE	4+
	47	M carcinoma	3 / 2	NE	n
15	48	M carcinoma	3 / 3	NE	n
	49	E carcinoma	2 / 3	N	4+
	50	E carcinoma	3 / 2	NE	4+
	51	E carcinoma	3 / 3	NE	4+
	52	C carcinoma	1 / 3	N	4+
20	53	C carcinoma	1 / 1	N	4+
	54	C carcinoma	3 / 2	P	4+

<sup>a</sup>S, serous; M, mucinous; E, endometrioid; C, clear cell; <sup>b</sup>LN, lymph node metastasis; P, positive; N, negative; NE, not examined; <sup>c</sup>n, normal range = mean  $\pm$ 2SD; 2+, mean  $\pm$ 2SD to  $\pm$ 4SD; 4+, mean  $\pm$ 4SD or greater.



**TABLE 6**Overexpression of hepsin in normal ovaries and ovarian tumors

Type	N	Hepsin	Ratio of
		<u>Overexpression</u>	<u>to <math>\beta</math>-tubulin</u>
Normal	10	0 (0%)	0.06 $\pm$ 0.05
LMP	12	7 (58.3%)	0.26 $\pm$ 0.19
Serous	7	6 (85.7%)	0.34 $\pm$ 0.20
Mucinous	5	1 (20.0%)	0.14 $\pm$ 0.12
Carcinomas	32	27 (84.4%)	0.46 $\pm$ 0.29
Serous	19	18 (94.7%)	0.56 $\pm$ 0.32
Mucinous	7	3 (42.9%)	0.26 $\pm$ 0.22
Endometrioid	3	3 (100%)	0.34 $\pm$ 0.01
Clear Cell	3	3 (100%)	0.45 $\pm$ 0.08

**EXAMPLE 14**Expression of SCCE and PUMP-1

Studies using both SCCE-specific primers (Figure 8) and PUMP-specific primers (Figure 9) indicate overexpression of these proteases in ovarian carcinomas.

**EXAMPLE 15**Summary of known proteases detected herein

Most of the proteases described herein were identified

from the sense-His/antisense-Ser primer pair, yielding a 500 bp PCR product (Figure 1, Lane 4). Some of the enzymes are familiar, a short summary of each follows.

### *Hepsin*

5                   Hepsin is a trypsin-like serine protease cloned from hepatoma cells. Hepsin is an extracellular protease (the enzyme includes a secretion signal sequence) which is anchored in the plasma membrane by its amino terminal domain, thereby exposing its catalytic domain to the extracellular matrix. Hepsin has also  
10   been shown to be expressed in breast cancer cell lines and peripheral nerve cells. Hepsin has never before been associated with ovarian carcinoma. Specific primers for the hepsin gene were synthesized and the expression of hepsin examined using Northern blots of fetal tissue and ovarian tissue (both normal and ovarian  
15   carcinoma).

                  Figure 10A shows that hepsin was expressed in ovarian carcinomas of different histologic types, but not in normal ovary. Figure 10B shows that hepsin was expressed in fetal liver and fetal kidney as anticipated, but at very low levels or not at all in fetal  
20   brain and lung. Figure 10C shows that hepsin overexpression is not observed in normal adult tissue. Slight expression above the background level is observed in the adult prostate. The mRNA identified in both Northern blots was the appropriate size for the hepsin transcript. The expression of hepsin was examined in 10  
25   normal ovaries and 44 ovarian tumors using specific primers to  $\beta$ -tubulin and hepsin in a quantitative PCR assay, and found it to be linear over 35 cycles. Expression is presented as the ratio of  $^{32}\text{P}$ -hepsin band to the internal control, the  $^{32}\text{P}$ - $\beta$ -tubulin band.

Hepsin expression was investigated in normal (N), mucinous (M) and serous (S) low malignant potential (LMP) tumors and carcinomas (CA). Figure 11A shows quantitative PCR of hepsin and internal control  $\beta$ -tubulin. Figure 11B shows the ratio of  
5 hepsin: $\beta$ -tubulin expression in normal ovary, LMP tumor, and ovarian carcinoma. It was observed that Hepsin mRNA expression levels were significantly elevated in LMP tumors, ( $p < 0.005$ ) and carcinomas ( $p < 0.0001$ ) compared to levels in normal ovary. All 10 cases of normal ovaries showed a relatively low level of hepsin  
10 mRNA expression.

Hepsin mRNA is highly overexpressed in most histopathologic types of ovarian carcinomas including some low malignant potential tumors (see Figures 11A & 11B). Most noticeably, hepsin is highly expressed in serous, endometrioid and  
15 clear cell tumors tested. It is highly expressed in some mucinous tumors, but it is not overexpressed in the majority of such tumors.

#### Stratum corneum chymotrypsin enzyme (SCCE)

The PCR product identified was the catalytic domain of  
20 the sense-His/antisense-Ser of the stratum corneum chymotrypsin enzyme. This extracellular protease was cloned, sequenced and shown to be expressed on the surface of keratinocytes in the epidermis. Stratum corneum chymotrypsin enzyme is a chymotrypsin-like serine protease whose function is suggested to be  
25 in the catalytic degradation of intercellular cohesive structures in the stratum corneum layer of the skin. This degradation allows continuous shedding (desquamation) of cells from the skin surface. The subcellular localization of stratum corneum chymotrypsin

enzyme is in the upper granular layer in the stratum corneum of normal non-palmoplantar skin and in the cohesive parts of hypertrophic plantar stratum corneum. Stratum corneum chymotrypsin enzyme is exclusively associated with the stratum  
5 corneum and has not so far been shown to be expressed in any carcinomatous tissues.

Northern blots were probed with the PCR product to determine expression of stratum corneum chymotrypsin enzyme in fetal tissue and ovarian carcinoma (Figures 12A & 12B). Noticeably,  
10 detection of stratum corneum chymotrypsin enzyme messenger RNA on the fetal Northern was almost non-existent (a problem with the probe or the blot was excluded by performing the proper controls). A faint band appeared in fetal kidney. On the other hand, stratum corneum chymotrypsin enzyme mRNA is abundant in the ovarian  
15 carcinoma mRNA (Figure 12B). Two transcripts of the correct size are observed for stratum corneum chymotrypsin enzyme. The same panel of cDNA used for hepsin analysis was used for stratum corneum chymotrypsin enzyme expression.

No stratum corneum chymotrypsin enzyme expression  
20 was detected in the normal ovary lane of the Northern blot. A comparison of all candidate genes, including a loading marker ( $\beta$ -tubulin), was shown to confirm that this observation was not a result of a loading bias. Quantitative PCR using stratum corneum chymotrypsin enzyme primers, along with  $\beta$ -tubulin internal control  
25 primers, confirmed the overexpression of stratum corneum chymotrypsin enzyme mRNA in carcinoma of the ovary with no expression in normal ovarian tissue (Figure 13).

Figure 13A shows a comparison using quantitative PCR of



stratum corneum chymotrypsin enzyme cDNA from normal ovary and ovarian carcinomas. Figure 13B shows the ratio of stratum corneum chymotrypsin enzyme to the  $\beta$ -tubulin internal standard in 10 normal and 44 ovarian carcinoma tissues. Again, it is observed that stratum corneum chymotrypsin enzyme is highly overexpressed in ovarian carcinoma cells. It is also noted that some mucinous tumors overexpress stratum corneum chymotrypsin enzyme, but the majority do not.

#### 10 Protease M

Protease M was identified from subclones of the His--ser primer pair. This protease was first cloned by Anisowicz, *et al.*, [*Molecular Medicine*, 2, 624-636 (1996)] and shown to be overexpressed in carcinomas. A preliminary evaluation indicates that this enzyme is overexpressed in ovarian carcinoma (Figure 14).

#### Cofactor I and Complement factor B

Several serine proteases associated with the coagulation pathway were also subcloned. Examination of normal and ovarian carcinomas by quantitative PCR for expression of these enzymes, it was noticeable that this mRNA was not clearly overexpressed in ovarian carcinomas when compared to normal ovarian tissue. It should be noted that the same panel of tumors was used for the evaluation of each candidate protease.

25

**EXAMPLE 16**Summary of previously unknown proteases detected hereinTADG-12

5 TADG-12 was identified from the primer pairs, sense-His/antisense-Asp (see Figure 1, Lanes 1 & 2). Upon subcloning both PCR products in lane 2, the 200 bp product had a unique protease-like sequence not included in GenBank. This 200 bp product contains many of the conserved amino acids common for  
10 the His-Asp domain of the family of serine proteins. The second and larger PCR product (300 bp) was shown to have a high degree of homology with TADG-12 (His-Asp sequence), but also contained approximately 100 bp of unique sequence. Synthesis of specific primers and the sequencing of the subsequent PCR products from  
15 three different tumors demonstrated that the larger PCR product (present in about 50% of ovarian carcinomas) includes an insert of about 100 bp near the 5' end (and near the histidine) of the sequence. This insert may be a retained genomic intron because of the appropriate position of splice sites and the fact that the insert  
20 does not contain an open reading frame (see Figure 15). This suggests the possibility of a splice site mutation which gives rise to retention of the intron, or a translocation of a sequence into the TADG-12 gene in as many as half of all ovarian carcinomas.

25 TADG-13 and TADG-14

Specific primers were synthesized for TADG-13 and TADG-14 to evaluate expression of genes in normal and ovarian carcinoma tissue. Northern blot analysis of ovarian tissues indicates

the transcript for the TADG-14 gene is approximately 1.4 kb and is expressed in ovarian carcinoma tissues (Figure 16A) with no noticeable transcript presence in normal tissue. In quantitative PCR studies using specific primers, increased expression of TADG-14 in ovarian carcinoma tissues was noted compared to a normal ovary (Figure 16B). The presence of a specific PCR product for TADG-14 in both an HeLa library and an ovarian carcinoma library was also confirmed. Several candidate sequences corresponding to TADG-14 have been screened and isolated from the HeLa library.

Clearly from sequence homology, these genes fit into the family of serine proteases. TADG-13 and -14 are, however, heretofore undocumented genes which the specific primers of the invention allow to be evaluated in normal and tumor cells, and with which the presence or absence of expression of these genes is useful in the diagnosis or treatment selection for specific tumor types.

### PUMP-1

In a similar strategy using redundant primers to metal binding domains and conserved histidine domains, a differentially expressed PCR product identical to matrix metallo-protease 7 (MMP-7) was identified, herein called PUMP-1. Using specific primers for PUMP-1, PCR produced a 250 bp product for Northern blot analysis.

PUMP-1 is differentially expressed in fetal lung and kidney tissues. Figure 17A shows the expression of PUMP-1 in human fetal tissue, while no transcript could be detected in either fetal brain or fetal liver. Figure 17B compares PUMP-1 expression in normal ovary and carcinoma subtypes using Northern blot analysis. Notably, PUMP-1 is expressed in ovarian carcinoma tissues, and

again, the presence of a transcript in normal tissue was not detected. Quantitative PCR comparing normal versus ovarian carcinoma expression of the PUMP-1 mRNA indicates that this gene is highly expressed in serous carcinomas, including most low malignant serous tumors, and is, again, expressed to a lesser extent in mucinous tumors (see Figures 18A & 18B). PUMP-1, however, is so far the protease most frequently found overexpressed in mucinous tumors (See Table 7).

#### 10 Cathepsin-L

Using redundant cysteine protease primers to conserved domains surrounding individual cysteine and histidine residues, the cathepsin-L protease was identified in several serous carcinomas. An initial examination of the expression of cathepsin L in normal and ovarian tumor tissue indicates that transcripts for the cathepsin-L protease are present in both normal and tumor tissues (Figure 19). However, its presence or absence in combination with other proteases of the present invention permits identification of specific tumor types and treatment choices.

20

#### Discussion

Redundant primers to conserved domains of serine, metallo-, and cysteine proteases have yielded a set of genes whose mRNAs are overexpressed in ovarian carcinoma. The genes which are clearly overexpressed include the serine proteases hepsin, stratum corneum chymotrypsin enzyme, protease M TADG12, TADG14 and the metallo-protease PUMP-1 (see Figure 19 and Table 7). Northern blot analysis of normal and ovarian carcinoma tissues,



summarized in Figure 14, indicated overexpression of hepsin, stratum corneum chymotrypsin enzyme, PUMP-1 and TADG-14. A  $\beta$ -tubulin probe to control for loading levels was included.

5

**TABLE 7**Overexpression of Proteases in Ovarian Tumors

	Type	N	Hepsin	SCCE	Pump-1	Protease M
	Normal	10	0% (0/10)	0% (0/10)	0% (0/10)	0% (0/10)
10	LMP	12	58.3% (7/12)	66.7% (8/12)	75.0% (9/12)	75% (9/12)
	serous	7	85.7% (6/7)	85.7% (6/7)	85.7% (6/7)	100% (7/7)
	mucinous	5	20.0% (1/5)	40.0% (2/5)	60% (3/5)	40.0% (2/5)
	Carcinoma	32	84.4% (27/32)	78.1% (25/32)	81.3% (26/32)	90.6% (29/32)
	serous	19	94.7% (18/19)	89.5% (17/19)	78.9% (15/19)	94.7% (18/19)
15	mucinous	7	42.9% (3/7)	28.6% (2/7)	71.4% (5/7)	85.7% (6/7)
	endometr.	3	100% (3/3)	100% (3/3)	100% (3/3)	100% (3/3)
	clear cell	3	100% (3/3)	100% (3/3)	100% (3/3)	67.7% (2/3)

20

For the most part, these proteins previously have not been associated with the extracellular matrix of ovarian carcinoma cells. No panel of proteases which might contribute to the growth, shedding, invasion and colony development of metastatic carcinoma has been previously described, including the three new candidate

25 serine proteases which are herein disclosed. The establishment of an extracellular protease panel associated with either malignant growth or malignant potential offers the opportunity for the identification of diagnostic or prognostic markers and for therapeutic intervention through inhibition or down regulation of

these proteases.

The availability of the instant gene-specific primers coding for the appropriate region of tumor specific proteases allows for the amplification of a specific cDNA probe using Northern and Southern analysis, and their use as markers to detect the presence of the cancer in tissue. The probes also allow more extensive evaluation of the expression of the gene in normal ovary versus low malignant potential tumor, as well as both high- and low-stage carcinomas. The evaluation of a panel of fresh frozen tissue from all the carcinoma subtypes (Table 4) allowed the determination of whether a protease is expressed predominantly in early stage disease or within specific carcinoma subtypes. It was also determined whether each gene's expression is confined to a particular stage in tumor progression and/or is associated with metastatic lesions. Detection of specific combinations of proteases is an identifying characteristic of the specific tumor types and yields valuable information for diagnoses and treatment selection. Particular tumor types may be more accurately diagnosed by the characteristic expression pattern of each specific tumor.

20

### **EXAMPLE 17**

#### **Peptide ranking**

For vaccine or immune stimulation, individual 9-mers to 11-mers of the hepsin protein were examined to rank the binding of individual peptides to the top 8 haplotypes in the general population (Parker et al., (1994)). The computer program used for this

25

analyses can be found at <[http://www-bimas.dcrt.nih.gov/molbio/hla\\_bind/](http://www-bimas.dcrt.nih.gov/molbio/hla_bind/)>. Table 8 shows the peptide ranking based upon the predicted half-life of each peptide's binding to a particular HLA allele. A larger half-life indicates a stronger association with that peptide and the particular HLA molecule. The hepsin peptides that strongly bind to an HLA allele are putative immunogens, and are used to inoculate an individual against hepsin.

10

**TABLE 8**Hepsin peptide ranking

HLA Type				Predicted	SEQ
	& Ranking	Start	Peptide	Dissociation <sub>1/2</sub>	ID No.
15	HLA A0201				
	1	170	SLGRWPWQV	521.640	28
	2	191	SLLSGDWVL	243.051	29
	3	229	GLQLGVQAV	159.970	30
	4	392	KVSDFREWI	134.154	31
20	5	308	VLQEARVPI	72.717	32
	6	130	RLLEVISVC	71.069	33
	7	98	ALTHSELDV	69.552	34
	8	211	VLSRWRVFA	46.451	35
	9	26	LLLLTAIGA	31.249	36
25	10	284	ALVDGKICT	30.553	37
	11	145	FLAAICQDC	22.853	38
	12	192	LLSGDWVLT	21.536	39
	13	20	ALTAGTLLL	21.362	40

WO 01/62271

PCT/US01/05703

	14	259	ALVHLSSPL	21.362	41
	15	277	CLPAAGQAL	21.362	42
	16	230	LQLGVQAVV	18.186	43
	17	268	PLTEYIQPV	14.429	44
5	18	31	AIGAASWAI	10.759	45
	19	285	LVDGKICTV	9.518	46
	20	27	LLTAIGAA	9.343	47
HLA A0205					
	1	191	SLLSGDWVL	25.200	48
10	2	163	IVGGRDTSL	23.800	49
	3	392	KVSDFREWI	18.000	50
	4	64	MVFDKTEGT	15.300	51
	5	236	AVVYHGGYL	14.000	52
	6	55	QVSSADARL	14.000	53
15	7	130	RLLEVISVC	9.000	54
	8	230	LQLGVQAVV	8.160	55
	9	20	ALTAGTLLL	7.000	56
	10	259	ALVHLSSPL	7.000	57
	11	277	CLPAAGQAL	7.000	58
20	12	17	KVAALTAGT	6.000	59
	13	285	LVDGKICTV	5.440	60
	14	308	VLQEARVPI	5.100	61
	15	27	LLTAIGAA	5.100	62
	16	229	GLQLGVQAV	4.000	63
25	17	313	RVPIISNDV	4.000	64
	18	88	LSCEEMGFL	3.570	65
	19	192	LLSGDWVLT	3.400	66
	20	284	ALVDGKICT	3.000	67



WO 01/62271

PCT/US01/05703

## HLA A1

	1	89	SCEEMGFLR	45.000	68
	2	58	SADARLMVF	25.000	69
	3	393	VSDFREWIF	7.500	70
5	4	407	HSEASGMVT	6.750	71
	5	137	VCDCPRGRF	5.000	72
	6	269	LTEYIQPVC	4.500	73
	7	47	DQEPLYPVQ	2.700	74
	8	119	CVDEGRLPH	2.500	75
10	9	68	KTEGTWRL	2.250	76
	10	101	HSELDVRTA	1.350	77
	11	250	NSEENSNDI	1.350	78
	12	293	VTGWGNTQY	1.250	79
	13	231	QLGVQAVVY	1.000	80
15	14	103	ELDVRTAGA	1.000	81
	15	378	GTGCALAQK	1.000	82
	16	358	VCEDSISRT	0.900	83
	17	264	SSPLPLTEY	0.750	84
	18	87	GLSCEEMGF	0.500	85
20	19	272	YIQPVCLPA	0.500	86
	20	345	GIDACQGDS	0.500	87

## HLA A24

	1	301	YYGQQAGVL	200.000	88
	2	238	VYHGGYLPF	100.000	89
25	3	204	CFPERNRVL	36.000	90
	4	117	FFCVDEGRL	20.000	91
	5	124	RLPHTQRLL	12.000	92
	6	80	RSNARVAGL	12.000	93

WO 01/62271

PCT/US01/05703

	7	68	KTEGTWRL1	2.000	94
	8	340	GYPEGGIDA	9.000	95
	9	242	GYLPFRDPN	9.000	96
	10	51	LYPVQVSSA	7.500	97
5	11	259	ALVHLSSPL	7.200	98
	12	277	CLPAAGQAL	7.200	99
	13	191	SLLSGDWVL	6.000	100
	14	210	RVLSRWRVF	6.000	101
	15	222	VAQASPHGL	6.000	102
10	16	236	AVVYHGGYL	6.000	103
	17	19	AALTAGTLL	6.000	104
	18	36	SWAIVAVLL	5.600	105
	19	35	ASWAIVAVL	5.600	106
	20	300	QYYGQQAGV	5.600	107
15	HLA B7				
	1	363	ISRTPRWRL	90.000	108
	2	366	TPRWRLCGI	80.000	109
	3	236	AVVYHGGYL	60.000	110
	4	13	CSRPKVAAL	40.000	111
20	5	179	SLRYDGAHL	40.000	112
	6	43	LLRSDQEPL	40.000	113
	7	19	AALTAGTLL	36.000	114
	8	55	QVSSADARL	20.000	115
	9	163	IVGGRDTSL	20.000	116
25	10	140	CPRGRFLAA	20.000	117
	11	20	ALTAGTLLL	12.000	118
	12	409	EASGMVTQL	12.000	119
	13	259	ALVHLSSPL	12.000	120

WO 01/62271

PCT/US01/05703

	14	35	ASWAIVAVL	12.000	121
	15	184	GAHLCGGSL	12.000	122
	16	18	VAALTAGTL	12.000	123
	17	222	VAQASPHGL	12.000	124
5	18	224	QASPHGLQL	12.000	125
	19	265	SPLPLTEYI	8.000	126
	20	355	GPFVCEDSI	8.00	127
HLA B8					
	1	13	CSRPKVAAL	80.000	128
10	2	366	TPRWRLCGI	80.000	129
	3	140	CPRGRFLAA	16.000	130
	4	152	DCGRRKLPV	4.800	131
	5	363	ISRTPRWRL	4.000	132
	6	163	IVGGRDTSI	4.000	133
15	7	331	QIKPKMFCA	4.000	134
	8	80	RSNARVAGL	2.000	135
	9	179	SLRYDGAHL	1.600	136
	10	43	LLRSDQEPL	1.600	137
	11	409	EASGMVTQL	1.600	138
20	12	311	EARVPIISN	0.800	139
	13	222	VAQASPHGL	0.800	140
	14	19	AALTAGTLL	0.800	141
	15	18	VAALTAGTL	0.800	142
	16	184	GAHLCGGSL	0.800	143
25	17	224	QASPHGLQL	0.800	144
	18	82	NARVAGLSC	0.800	145
	19	204	CFPERNRVL	0.600	146
	20	212	LSRWRVFAG	0.400	147

WO 01/62271

PCT/US01/05703

## HLA B2702

	1	172	GRWPWQVSL	300.000	148
	2	44	LRSDQEPLY	200.00	149
	3	155	RRKLPVDRI	180.000	150
5	4	213	SRWRVFAGA	100.000	151
	5	166	GRDTS LGRW	100.000	152
	6	369	WRLCGIVSW	100.000	153
	7	180	LR YDGAHLC	100.000	154
	8	96	LRALTHSEL	60.000	155
10	9	396	FREWIFQAI	60.000	156
	10	123	GRLPHTQRL	60.000	157
	11	207	ERNRVLSRW	30.000	158
	12	209	NRVLSRWRV	20.000	159
	13	14	SRPKVAALT	20.000	160
15	14	106	VRTAGANGT	20.000	161
	15	129	QRLLEVISV	20.000	162
	16	349	CQGDSGGPF	20.000	163
	17	61	ARLMVFDKT	20.000	164
	18	215	WRVFAGAVA	20.000	165
20	19	143	GRFLAAICQ	10.000	166
	20	246	FRDPNSEEN	10.000	167

## HLA B4403

	1	132	LEVISVCDC	36.000	168
	2	91	EEMGFLRAL	18.000	169
25	3	264	SSPLPLTEY	13.500	170
	4	310	QEARVPIIS	12.000	171
	5	319	NDVCNGADF	10.000	172
	6	4	KEGGRTVPC	9.000	173



	7	251	SEENSNDIA	8.000	174
	8	256	NDIALVHLS	7.500	175
	9	294	TGWGNTQYY	6.750	176
	10	361	DSISRTPRW	6.750	177
5	11	235	QAVVYHGGY	6.000	178
	12	109	AGANGTSGF	6.000	179
	13	270	TEYIQPVCL	6.000	180
	14	174	WPWQVSLRY	4.500	181
	15	293	VTGWGNTQY	4.500	182
10	16	69	TEGTWRLLC	4.000	183
	17	90	CEEMGFLRA	4.000	184
	18	252	EENSNDIAL	4.000	185
	19	48	QEPLYPVQV	4.000	186
	20	102	SELDVRTAG	3.600	187

15

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as

limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

## SEQUENCE LISTING

<110> O'Brien, Timothy J.  
 <120> Compositions and Methods for the Early Diagnosis  
 of Ovarian Cancer  
 <130> D6223CIPA/PCT  
 <141> 2001-02-20  
 <150> 09/510,738  
 <151> 2000-02-22  
 <160> 188  
 <210> 1  
 <211> 23  
 <212> DNA  
 <213> Artificial sequence  
 <220>  
 <221> primer\_bind  
 <222> 6, 9, 12, 15, 18  
 <223> sense oligonucleotide primer for amplifying serine  
 proteases, n = Inosine  
 <400> 1  
 tgggtngtna cngcngcnca ytg 23  
 <210> 2  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence  
 <220>  
 <221> primer\_bind  
 <222> 3, 6, 9, 12, 15, 18  
 <223> antisense oligonucleotide primer for amplifying serine  
 proteases, n = Inosine  
 <400> 2  
 arnarngcna tntcnttncc 20  
 <210> 3  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence  
 <220>  
 <221> primer\_bind  
 <222> 3, 6, 9, 12, 18  
 <223> antisense oligonucleotide primer for amplifying serine  
 proteases, n = Inosine

<400> 3  
 arnggncnc cnswrtcnc 20

<210> 4  
 <211> 24  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <221> primer\_bind  
 <222> 6, 15, 18  
 <223> sense oligonucleotide primer for amplifying cysteine  
 proteases, n = Inosine

<400> 4  
 carggncart gyggnewsntg ytgg 24

<210> 5  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <221> primer\_bind  
 <222> 3, 6, 15  
 <223> antisense oligonucleotide primer for amplifying cysteine  
 proteases, n = Inosine

<400> 5  
 tancncrcrt trcancctc 20

<210> 6  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <221> primer\_bind  
 <222> 3, 6, 12, 15, 18  
 <223> sense oligonucleotide primer for amplifying metallo-  
 proteases, n = Inosine

<400> 6  
 ccnmgntgyg gnrwnccnga 20

<210> 7  
 <211> 17  
 <212> DNA  
 <213> Artificial sequence

<220>



<221> primer\_bind  
<222> 6, 9, 11  
<223> antisense oligonucleotide primer for amplifying metallo-  
proteases, n = Inosine

<400> 7  
ttrtgncna nytcrtg 17

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for hepsin

<400> 8  
tgtcccgatg gcgagtgttt 20

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for hepsin

<400> 9  
cctggtggcc atagtactgc 20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for SCCE

<400> 10  
agatgaatga gtacaccgtg 20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for SCCE

WO 01/62271

PCT/US01/05703

<400> 11  
ccagtaagtc cttgtaaacc 20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for CompB

<400> 12  
aaggacacg agagctgtat 20

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for CompB

<400> 13  
aagtggtagt tggaggaagc 20

<210> 14  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for Cath-L

<400> 14  
attggagaga gaaaggctac 20

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for Cath-L

<400> 15  
cttgggattg tacttacagg 20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for PUMP-1

<400> 16  
cttccaaagt ggtcacctac 20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for PUMP-1

<400> 17  
ctagactgct accatccgtc 20

<210> 18  
<211> 17  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for  $\beta$ -tubulin

<400> 18  
tgcattgaca acgaggc 17

<210> 19  
<211> 17  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for  $\beta$ -tubulin

<400> 19  
ctgtccttgac attgttg 17

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for Protease M

<400> 20  
ctgtgatcca ccctgactat 20

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for Protease M

<400> 21  
caggtggatg tatgcacact 20

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for TADG-12

<400> 22  
gcgcactgtg tttatgagat 20

<210> 23  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for TADG-12

<400> 23  
ctcttttggt tgtacttgct 20

<210> 24  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for TADG-13

<400> 24  
tgaggacat cattatgcac 20

<210> 25  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for TADG-13



WO 01/62271

PCT/US01/05703

<400> 25  
caagttttcc ccataattgg 20

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> sense oligonucleotide primer specific for TADG-14

<400> 26  
acagtacgcc tgggagacca 20

<210> 27  
<211> 20  
<212> DNA  
<213> Artificial sequence

<220>  
<223> antisense oligonucleotide primer specific for TADG-14

<400> 27  
ctgagacggt gcaattctgg 20

<210> 28  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 170-178 of the hepsin protein

<400> 28  
Ser Leu Gly Arg Trp Pro Trp Gln Val  
5

<210> 29  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 191-199 of the hepsin protein

<400> 29  
Ser Leu Leu Ser Gly Asp Trp Val Leu  
5

<210> 30

WO 01/62271

PCT/US01/05703

<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 229-237 of the hepsin protein

<400> 30  
Gly Leu Gln Leu Gly Val Gln Ala Val  
5

<210> 31  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 392-400 of the hepsin protein

<400> 31  
Lys Val Ser Asp Phe Arg Glu Trp Ile  
5

<210> 32  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 308-316 of the hepsin protein

<400> 32  
Val Leu Gln Glu Ala Arg Val Pro Ile  
5

<210> 33  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 130-138 of the hepsin protein

<400> 33  
Arg Leu Leu Glu Val Ile Ser Val Cys  
5

<210> 34  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

WO 01/62271

PCT/US01/05703

<220>  
<223> Residues 98-106 of the hepsin protein

<400> 34  
Ala Leu Thr His Ser Glu Leu Asp Val  
5

<210> 35  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 211-219 of the hepsin protein

<400> 35  
Val Leu Ser Arg Trp Arg Val Phe Ala  
5

<210> 36  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 26-34 of the hepsin protein

<400> 36  
Leu Leu Leu Leu Thr Ala Ile Gly Ala  
5

<210> 37  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 284-292 of the hepsin protein

<400> 37  
Ala Leu Val Asp Gly Lys Ile Cys Thr  
5

<210> 38  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 145-153 of the hepsin protein

<400> 38

WO 01/62271

PCT/US01/05703

Phe Leu Ala Ala Ile Cys Gln Asp Cys  
5

<210> 39  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 192-200 of the hepsin protein

<400> 39  
Leu Leu Ser Gly Asp Trp Val Leu Thr  
5

<210> 40  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 20-28 of the hepsin protein

<400> 40  
Ala Leu Thr Ala Gly Thr Leu Leu Leu  
5

<210> 41  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 259-267 of the hepsin protein

<400> 41  
Ala Leu Val His Leu Ser Ser Pro Leu  
5

<210> 42  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 277-285 of the hepsin protein

<400> 42  
Cys Leu Pro Ala Ala Gly Gln Ala Leu  
5



WO 01/62271

PCT/US01/05703

<210> 43  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 230-238 of the hepsin protein

<400> 43  
Leu Gln Leu Gly Val Gln Ala Val Val  
5

<210> 44  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 268-276 of the hepsin protein

<400> 44  
Pro Leu Thr Glu Tyr Ile Gln Pro Val  
5

<210> 45  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 31-39 of the hepsin protein

<400> 45  
Ala Ile Gly Ala Ala Ser Trp Ala Ile  
5

<210> 46  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 285-293 of the hepsin protein

<400> 46  
Leu Val Asp Gly Lys Ile Cys Thr Val  
5

<210> 47  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 27-35 of the hepsin protein

&lt;400&gt; 47

Leu Leu Leu Thr Ala Ile Gly Ala Ala  
5

&lt;210&gt; 48

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 191-199 of the hepsin protein

&lt;400&gt; 48

Ser Leu Leu Ser Gly Asp Trp Val Leu  
5

&lt;210&gt; 49

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 163-171 of the hepsin protein

&lt;400&gt; 49

Ile Val Gly Gly Arg Asp Thr Ser Leu  
5

&lt;210&gt; 50

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 392-400 of the hepsin protein

&lt;400&gt; 50

Lys Val Ser Asp Phe Arg Glu Trp Ile  
5

&lt;210&gt; 51

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 64-72 of the hepsin protein

WO 01/62271

PCT/US01/05703

<400> 51  
Met Val Phe Asp Lys Thr Glu Gly Thr  
5

<210> 52  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 236-244 of the hepsin protein

<400> 52  
Ala Val Val Tyr His Gly Gly Tyr Leu  
5

<210> 53  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 55-63 of the hepsin protein

<400> 53  
Gln Val Ser Ser Ala Asp Ala Arg Leu  
5

<210> 54  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 130-138 of the hepsin protein

<400> 54  
Arg Leu Leu Glu Val Ile Ser Val Cys  
5

<210> 55  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 230-238 of the hepsin protein

<400> 55  
Leu Gln Leu Gly Val Gln Ala Val Val  
5

WO 01/62271

PCT/US01/05703

<210> 56  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 20-28 of the hepsin protein

<400> 56  
Ala Leu Thr Ala Gly Thr Leu Leu Leu  
5

<210> 57  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 259-267 of the hepsin protein

<400> 57  
Ala Leu Val His Leu Ser Ser Pro Leu  
5

<210> 58  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 277-285 of the hepsin protein

<400> 58  
Cys Leu Pro Ala Ala Gly Gln Ala Leu  
5

<210> 59  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 17-25 of the hepsin protein

<400> 59  
Lys Val Ala Ala Leu Thr Ala Gly Thr  
5

<210> 60  
<211> 9  
<212> PRT



WO 01/62271

PCT/US01/05703

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 285-293 of the hepsin protein

&lt;400&gt; 60

Leu Val Asp Gly Lys Ile Cys Thr Val  
5

&lt;210&gt; 61

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 308-316 of the hepsin protein

&lt;400&gt; 61

Val Leu Gln Glu Ala Arg Val Pro Ile  
5

&lt;210&gt; 62

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 27-35 of the hepsin protein

&lt;400&gt; 62

Leu Leu Leu Thr Ala Ile Gly Ala Ala  
5

&lt;210&gt; 63

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 229-237 of the hepsin protein

&lt;400&gt; 63

Gly Leu Gln Leu Gly Val Gln Ala Val  
5

&lt;210&gt; 64

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 313-321 of the hepsin protein

WO 01/62271

PCT/US01/05703

<400> 64  
Arg Val Pro Ile Ile Ser Asn Asp Val  
5

<210> 65  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 88-96 of the hepsin protein

<400> 65  
Leu Ser Cys Glu Glu Met Gly Phe Leu  
5

<210> 66  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 192-200 of the hepsin protein

<400> 66  
Leu Leu Ser Gly Asp Trp Val Leu Thr  
5

<210> 67  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 284-292 of the hepsin protein

<400> 67  
Ala Leu Val Asp Gly Lys Ile Cys Thr  
5

<210> 68  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 89-97 of the hepsin protein

<400> 68  
Ser Cys Glu Glu Met Gly Phe Leu Arg  
5

WO 01/62271

PCT/US01/05703

<210> 69  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 58-66 of the hepsin protein

<400> 69  
Ser Ala Asp Ala Arg Leu Met Val Phe  
5

<210> 70  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 393-401 of the hepsin protein

<400> 70  
Val Ser Asp Phe Arg Glu Trp Ile Phe  
5

<210> 71  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 407-415 of the hepsin protein

<400> 71  
His Ser Glu Ala Ser Gly Met Val Thr  
5

<210> 72  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 137-145 of the hepsin protein

<400> 72  
Val Cys Asp Cys Pro Arg Gly Arg Phe  
5

<210> 73  
<211> 9  
<212> PRT

WO 01/62271

PCT/US01/05703

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 269-277 of the hepsin protein

&lt;400&gt; 73

Leu Thr Glu Tyr Ile Gln Pro Val Cys  
5

&lt;210&gt; 74

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 47-55 of the hepsin protein

&lt;400&gt; 74

Asp Gln Glu Pro Leu Tyr Pro Val Gln  
5

&lt;210&gt; 75

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 119-127 of the hepsin protein

&lt;400&gt; 75

Cys Val Asp Glu Gly Arg Leu Pro His  
5

&lt;210&gt; 76

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 68-76 of the hepsin protein

&lt;400&gt; 76

Lys Thr Glu Gly Thr Trp Arg Leu Leu  
5

&lt;210&gt; 77

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 101-109 of the hepsin protein



WO 01/62271

PCT/US01/05703

&lt;400&gt; 77

His Ser Glu Leu Asp Val Arg Thr Ala  
5

&lt;210&gt; 78

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 250-258 of the hepsin protein

&lt;400&gt; 78

Asn Ser Glu Glu Asn Ser Asn Asp Ile  
5

&lt;210&gt; 79

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 293-301 of the hepsin protein

&lt;400&gt; 79

Val Thr Gly Trp Gly Asn Thr Gln Tyr  
5

&lt;210&gt; 80

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 231-239 of the hepsin protein

&lt;400&gt; 80

Gln Leu Gly Val Gln Ala Val Val Tyr  
5

&lt;210&gt; 81

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 103-111 of the hepsin protein

&lt;400&gt; 81

Glu Leu Asp Val Arg Thr Ala Gly Ala  
5

&lt;210&gt; 82

WO 01/62271

PCT/US01/05703

<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 378-386 of the hepsin protein

<400> 82  
Gly Thr Gly Cys Ala Leu Ala Gln Lys  
5

<210> 83  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 358-366 of the hepsin protein

<400> 83  
Val Cys Glu Asp Ser Ile Ser Arg Thr  
5

<210> 84  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 264-272 of the hepsin protein

<400> 84  
Ser Ser Pro Leu Pro Leu Thr Glu Tyr  
5

<210> 85  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 87-95 of the hepsin protein

<400> 85  
Gly Leu Ser Cys Glu Glu Met Gly Phe  
5

<210> 86  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 272-280 of the hepsin protein

&lt;400&gt; 86

Tyr Ile Gln Pro Val Cys Leu Pro Ala  
5

&lt;210&gt; 87

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 345-353 of the hepsin protein

&lt;400&gt; 87

Gly Ile Asp Ala Cys Gln Gly Asp Ser  
5

&lt;210&gt; 88

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 301-309 of the hepsin protein

&lt;400&gt; 88

Tyr Tyr Gly Gln Gln Ala Gly Val Leu  
5

&lt;210&gt; 89

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 238-246 of the hepsin protein

&lt;400&gt; 89

Val Tyr His Gly Gly Tyr Leu Pro Phe  
5

&lt;210&gt; 90

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 204-212 of the hepsin protein

&lt;400&gt; 90

WO 01/62271

PCT/US01/05703

Cys Phe Pro Glu Arg Asn Arg Val Leu  
5

<210> 91  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 117-125 of the hepsin protein

<400> 91  
Phe Phe Cys Val Asp Glu Gly Arg Leu  
5

<210> 92  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 124-132 of the hepsin protein

<400> 92  
Arg Leu Pro His Thr Gln Arg Leu Leu  
5

<210> 93  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 80-88 of the hepsin protein

<400> 93  
Arg Ser Asn Ala Arg Val Ala Gly Leu  
5

<210> 94  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 68-76 of the hepsin protein

<400> 94  
Lys Thr Glu Gly Thr Trp Arg Leu Leu  
5



WO 01/62271

PCT/US01/05703

<210> 95  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 340-348 of the hepsin protein

<400> 95  
Gly Tyr Pro Glu Gly Gly Ile Asp Ala  
5

<210> 96  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 242-250 of the hepsin protein

<400> 96  
Gly Tyr Leu Pro Phe Arg Asp Pro Asn  
5

<210> 97  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 51-59 of the hepsin protein

<400> 97  
Leu Tyr Pro Val Gln Val Ser Ser Ala  
5

<210> 98  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 259-267 of the hepsin protein

<400> 98  
Ala Leu Val His Leu Ser Ser Pro Leu  
5

<210> 99  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 277-285 of the hepsin protein

<400> 99  
Cys Leu Pro Ala Ala Gly Gln Ala Leu  
5

<210> 100  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 191-199 of the hepsin protein

<400> 100  
Ser Leu Leu Ser Gly Asp Trp Val Leu  
5

<210> 101  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 210-218 of the hepsin protein

<400> 101  
Arg Val Leu Ser Arg Trp Arg Val Phe  
5

<210> 102  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 222-230 of the hepsin protein

<400> 102  
Val Ala Gln Ala Ser Pro His Gly Leu  
5

<210> 103  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 236-244 of the hepsin protein

WO 01/62271

PCT/US01/05703

<400> 103  
Ala Val Val Tyr His Gly Gly Tyr Leu  
5

<210> 104  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 19-27 of the hepsin protein

<400> 104  
Ala Ala Leu Thr Ala Gly Thr Leu Leu  
5

<210> 105  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 36-44 of the hepsin protein

<400> 105  
Ser Trp Ala Ile Val Ala Val Leu Leu  
5

<210> 106  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 35-43 of the hepsin protein

<400> 106  
Ala Ser Trp Ala Ile Val Ala Val Leu  
5

<210> 107  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 300-308 of the hepsin protein

<400> 107  
Gln Tyr Tyr Gly Gln Gln Ala Gly Val  
5

WO 01/62271

PCT/US01/05703

<210> 108  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 363-371 of the hepsin protein

<400> 108  
Ile Ser Arg Thr Pro Arg Trp Arg Leu  
5

<210> 109  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 366-374 of the hepsin protein

<400> 109  
Thr Pro Arg Trp Arg Leu Cys Gly Ile  
5

<210> 110  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 236-244 of the hepsin protein

<400> 110  
Ala Val Val Tyr His Gly Gly Tyr Leu  
5

<210> 111  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 13-21 of the hepsin protein

<400> 111  
Cys Ser Arg Pro Lys Val Ala Ala Leu  
5

<210> 112  
<211> 9  
<212> PRT



WO 01/62271

PCT/US01/05703

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 179-187 of the hepsin protein

&lt;400&gt; 112

Ser Leu Arg Tyr Asp Gly Ala His Leu

5

&lt;210&gt; 113

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 43-51 of the hepsin protein

&lt;400&gt; 113

Leu Leu Arg Ser Asp Gln Glu Pro Leu

5

&lt;210&gt; 114

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 19-27 of the hepsin protein

&lt;400&gt; 114

Ala Ala Leu Thr Ala Gly Thr Leu Leu

5

&lt;210&gt; 115

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 55-63 of the hepsin protein

&lt;400&gt; 115

Gln Val Ser Ser Ala Asp Ala Arg Leu

5

&lt;210&gt; 116

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 163-171 of the hepsin protein

WO 01/62271

PCT/US01/05703

<400> 116  
Ile Val Gly Gly Arg Asp Thr Ser Leu  
5

<210> 117  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 140-148 of the hepsin protein

<400> 117  
Cys Pro Arg Gly Arg Phe Leu Ala Ala  
5

<210> 118  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 20-28 of the hepsin protein

<400> 118  
Ala Leu Thr Ala Gly Thr Leu Leu Leu  
5

<210> 119  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 409-417 of the hepsin protein

<400> 119  
Glu Ala Ser Gly Met Val Thr Gln Leu  
5

<210> 120  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 259-267 of the hepsin protein

<400> 120  
Ala Leu Val His Leu Ser Ser Pro Leu

5

<210> 121  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 35-43 of the hepsin protein

<400> 121  
Ala Ser Trp Ala Ile Val Ala Val Leu  
5

<210> 122  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 184-192 of the hepsin protein

<400> 122  
Gly Ala His Leu Cys Gly Gly Ser Leu  
5

<210> 123  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 18-26 of the hepsin protein

<400> 123  
Val Ala Ala Leu Thr Ala Gly Thr Leu  
5

<210> 124  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 222-230 of the hepsin protein

<400> 124  
Val Ala Gln Ala Ser Pro His Gly Leu  
5

<210> 125

WO 01/62271

PCT/US01/05703

<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 224-232 of the hepsin protein

<400> 125  
Gln Ala Ser Pro His Gly Leu Gln Leu  
5

<210> 126  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 265-273 of the hepsin protein

<400> 126  
Ser Pro Leu Pro Leu Thr Glu Tyr Ile  
5

<210> 127  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 355-363 of the hepsin protein

<400> 127  
Gly Pro Phe Val Cys Glu Asp Ser Ile  
5

<210> 128  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 13-21 of the hepsin protein

<400> 128  
Cys Ser Arg Pro Lys Val Ala Ala Leu  
5

<210> 129  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

WO 01/62271

PCT/US01/05703

&lt;220&gt;

&lt;223&gt; Residues 366-374 of the hepsin protein

&lt;400&gt; 129

Thr Pro Arg Trp Arg Leu Cys Gly Ile  
5

&lt;210&gt; 130

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 140-148 of the hepsin protein

&lt;400&gt; 130

Cys Pro Arg Gly Arg Phe Leu Ala Ala  
5

&lt;210&gt; 131

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 152-160 of the hepsin protein

&lt;400&gt; 131

Asp Cys Gly Arg Arg Lys Leu Pro Val  
5

&lt;210&gt; 132

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 363-371 of the hepsin protein

&lt;400&gt; 132

Ile Ser Arg Thr Pro Arg Trp Arg Leu  
5

&lt;210&gt; 133

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 133-141 of the hepsin protein

&lt;400&gt; 133



WO 01/62271

PCT/US01/05703

Ile Val Gly Gly Arg Asp Thr Ser Leu  
5

<210> 134  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 331-339 of the hepsin protein

<400> 134  
Gln Ile Lys Pro Lys Met Phe Cys Ala  
5

<210> 135  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 80-88 of the hepsin protein

<400> 135  
Arg Ser Asn Ala Arg Val Ala Gly Leu  
5

<210> 136  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 179-187 of the hepsin protein

<400> 136  
Ser Leu Arg Tyr Asp Gly Ala His Leu  
5

<210> 137  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 43-51 of the hepsin protein

<400> 137  
Leu Leu Arg Ser Asp Gln Glu Pro Leu  
5

WO 01/62271

PCT/US01/05703

<210> 138  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 409-417 of the hepsin protein

<400> 138  
Glu Ala Ser Gly Met Val Thr Gln Leu  
5

<210> 139  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 311-319 of the hepsin protein

<400> 139  
Glu Ala Arg Val Pro Ile Ile Ser Asn  
5

<210> 140  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 222-230 of the hepsin protein

<400> 140  
Val Ala Gln Ala Ser Pro His Gly Leu  
5

<210> 141  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 19-27 of the hepsin protein

<400> 141  
Ala Ala Leu Thr Ala Gly Thr Leu Leu  
5

<210> 142  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 18-26 of the hepsin protein

<400> 142  
Val Ala Ala Leu Thr Ala Gly Thr Leu  
5

<210> 143  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 184-192 of the hepsin protein

<400> 143  
Gly Ala His Leu Cys Gly Gly Ser Leu  
5

<210> 144  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 224-232 of the hepsin protein

<400> 144  
Gln Ala Ser Pro His Gly Leu Gln Leu  
5

<210> 145  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 82-90 of the hepsin protein

<400> 145  
Asn Ala Arg Val Ala Gly Leu Ser Cys  
5

<210> 146  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 204-212 of the hepsin protein

WO 01/62271

PCT/US01/05703

&lt;400&gt; 146

Cys Phe Pro Glu Arg Asn Arg Val Leu

5

&lt;210&gt; 147

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 212-220 of the hepsin protein

&lt;400&gt; 147

Leu Ser Arg Trp Arg Val Phe Ala Gly

5

&lt;210&gt; 148

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 172-180 of the hepsin protein

&lt;400&gt; 148

Gly Arg Trp Pro Trp Gln Val Ser Leu

5

&lt;210&gt; 149

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 44-52 of the hepsin protein

&lt;400&gt; 149

Leu Arg Ser Asp Gln Glu Pro Leu Tyr

5

&lt;210&gt; 150

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 155-163 of the hepsin protein

&lt;400&gt; 150

Arg Arg Lys Leu Pro Val Asp Arg Ile

5

WO 01/62271

PCT/US01/05703

<210> 151  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 213-221 of the hepsin protein

<400> 151  
Ser Arg Trp Arg Val Phe Ala Gly Ala  
5

<210> 152  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 166-174 of the hepsin protein

<400> 152  
Gly Arg Asp Thr Ser Leu Gly Arg Trp  
5

<210> 153  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 369-377 of the hepsin protein

<400> 153  
Trp Arg Leu Cys Gly Ile Val Ser Trp  
5

<210> 154  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 180-188 of the hepsin protein

<400> 154  
Leu Arg Tyr Asp Gly Ala His Leu Cys  
5

<210> 155  
<211> 9  
<212> PRT



WO 01/62271

PCT/US01/05703

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 96-104 of the hepsin protein

&lt;400&gt; 155

Leu Arg Ala Leu Thr His Ser Glu Leu

5

&lt;210&gt; 156

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 396-404 of the hepsin protein

&lt;400&gt; 156

Phe Arg Glu Trp Ile Phe Gln Ala Ile

5

&lt;210&gt; 157

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 123-131 of the hepsin protein

&lt;400&gt; 157

Gly Arg Leu Pro His Thr Gln Arg Leu

5

&lt;210&gt; 158

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 207-215 of the hepsin protein

&lt;400&gt; 158

Glu Arg Asn Arg Val Leu Ser Arg Trp

5

&lt;210&gt; 159

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

WO 01/62271

PCT/US01/05703

<223> Residues 209-217 of the hepsin protein

<400> 159

Asn Arg Val Leu Ser Arg Trp Arg Val  
5

<210> 160

<211> 9

<212> PRT

<213> *Homo sapiens*

<220>

<223> Residues 14-22 of the hepsin protein

<400> 160

Ser Arg Pro Lys Val Ala Ala Leu Thr  
5

<210> 161

<211> 9

<212> PRT

<213> *Homo sapiens*

<220>

<223> Residues 106-114 of the hepsin protein

<400> 161

Val Arg Thr Ala Gly Ala Asn Gly Thr  
5

<210> 162

<211> 9

<212> PRT

<213> *Homo sapiens*

<220>

<223> Residues 129-137 of the hepsin protein

<400> 162

Gln Arg Leu Leu Glu Val Ile Ser Val  
5

<210> 163

<211> 9

<212> PRT

<213> *Homo sapiens*

<220>

<223> Residues 349-357 of the hepsin protein

<400> 163

Cys Gln Gly Asp Ser Gly Gly Pro Phe

5

<210> 164  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 61-69 of the hepsin protein

<400> 164  
Ala Arg Leu Met Val Phe Asp Lys Thr  
5

<210> 165  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 215-223 of the hepsin protein

<400> 165  
Trp Arg Val Phe Ala Gly Ala Val Ala  
5

<210> 166  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 143-151 of the hepsin protein

<400> 166  
Gly Arg Phe Leu Ala Ala Ile Cys Gln  
5

<210> 167  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 246-254 of the hepsin protein

<400> 167  
Phe Arg Asp Pro Asn Ser Glu Glu Asn  
5

<210> 168

WO 01/62271

PCT/US01/05703

<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 132-140 of the hepsin protein

<400> 168  
Leu Glu Val Ile Ser Val Cys Asp Cys  
5

<210> 169  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 91-99 of the hepsin protein

<400> 169  
Glu Glu Met Gly Phe Leu Arg Ala Leu  
5

<210> 170  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 264-272 of the hepsin protein

<400> 170  
Ser Ser Pro Leu Pro Leu Thr Glu Tyr  
5

<210> 171  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 310-318 of the hepsin protein

<400> 171  
Gln Glu Ala Arg Val Pro Ile Ile Ser  
5

<210> 172  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

WO 01/62271

PCT/US01/05703

&lt;220&gt;

&lt;223&gt; Residues 319-327 of the hepsin protein

&lt;400&gt; 172

Asn Asp Val Cys Asn Gly Ala Asp Phe  
5

&lt;210&gt; 173

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 4-12 of the hepsin protein

&lt;400&gt; 173

Lys Glu Gly Gly Arg Thr Val Pro Cys  
5

&lt;210&gt; 174

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 251-259 of the hepsin protein

&lt;400&gt; 174

Ser Glu Glu Asn Ser Asn Asp Ile Ala  
5

&lt;210&gt; 175

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 256-264 of the hepsin protein

&lt;400&gt; 175

Asn Asp Ile Ala Leu Val His Leu Ser  
5

&lt;210&gt; 176

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 294-302 of the hepsin protein



WO 01/62271

PCT/US01/05703

<400> 176  
Thr Gly Trp Gly Asn Thr Gln Tyr Tyr  
5

<210> 177  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 361-369 of the hepsin protein

<400> 177  
Asp Ser Ile Ser Arg Thr Pro Arg Trp  
5

<210> 178  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 235-243 of the hepsin protein

<400> 178  
Gln Ala Val Val Tyr His Gly Gly Tyr  
5

<210> 179  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 109-117 of the hepsin protein

<400> 179  
Ala Gly Ala Asn Gly Thr Ser Gly Phe  
5

<210> 180  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 270-278 of the hepsin protein

<400> 180  
Thr Glu Tyr Ile Gln Pro Val Cys Leu  
5

WO 01/62271

PCT/US01/05703

<210> 181  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 174-182 of the hepsin protein

<400> 181  
Trp Pro Trp Gln Val Ser Leu Arg Tyr

<210> 182  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 293-301 of the hepsin protein

<400> 182  
Val Thr Gly Trp Gly Asn Thr Gln Tyr  
5

<210> 183  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 69-77 of the hepsin protein

<400> 183  
Thr Glu Gly Thr Trp Arg Leu Leu Cys  
5

<210> 184  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

<220>  
<223> Residues 90-98 of the hepsin protein

<400> 184  
Cys Glu Glu Met Gly Phe Leu Arg Ala  
5

<210> 185  
<211> 9  
<212> PRT  
<213> *Homo sapiens*

WO 01/62271

PCT/US01/05703

&lt;220&gt;

&lt;223&gt; Residues 252-260 of the hepsin protein

&lt;400&gt; 185

Glu Glu Asn Ser Asn Asp Ile Ala Leu  
5

&lt;210&gt; 186

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 48-56 of the hepsin protein

&lt;400&gt; 186

Gln Glu Pro Leu Tyr Pro Val Gln Val  
5

&lt;210&gt; 187

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; Residues 102-110 of the hepsin protein

&lt;400&gt; 187

Ser Glu Leu Asp Val Arg Thr Ala Gly  
5

&lt;210&gt; 188

&lt;211&gt; 1783

&lt;212&gt; DNA

<213> *Homo sapiens*

&lt;220&gt;

&lt;223&gt; full length cDNA of hepsin

&lt;400&gt; 188

tcgagcccgc	tttccagggga	ccctacctga	gggcccacag	gtgagggcagc	50
ctggcctagc	aggccccacg	ccaccgcctc	tgcctccagg	ccgcccgcctg	100
ctgcggggcc	accatgctcc	tgcccaggcc	tggagactga	cccgaacccc	150
gcactacctc	gaggctccgc	ccccacctgc	tggaccccag	ggtcccaccc	200
tggcccagga	ggtcagccag	ggaatcatta	acaagaggca	gtgacatggc	250
gcagaaggag	ggtggccgga	ctgtgccatg	ctgctccaga	cccaagggtgg	300
cagctctcac	tgcggggacc	ctgctacttc	tgacagccat	cggggcgga	350
tcctgggcca	ttgtggctgt	tctcctcagg	agtgaccagg	agccgctgta	400
cccagtgcag	gtcagctctg	cggacgctcg	gctcatggtc	tttgacaaga	450
cggaagggac	gtggcggctg	ctgtgctcct	cgcgctccaa	cgccagggta	500
gccggactca	gctgcgagga	gatgggcttc	ctcagggcac	tgaccactc	550
cgagctggac	gtgcgaacgg	cgggcgccaa	tggcacgtcg	ggcttcttct	600

gtgtggacga	ggggaggctg	ccccacaccc	agaggctgct	ggaggatcatc	650
tccgtgtgtg	attgccccag	aggccgtttc	ttggccgcca	tctgccaaga	700
ctgtggccgc	aggaagctgc	ccgtggaccg	catcgtggga	ggccgggaca	750
ccagcttggg	ccggtggccg	tggcaagtca	gccttcgcta	tgatggagca	800
cacctctgtg	ggggatccct	gctctccggg	gactgggtgc	tgacagccgc	850
ccactgcttc	ccggagcgga	accgggtcct	gtcccgatgg	cgagtgtttg	900
ccggtgccgt	ggcccaggcc	tctccccacg	gtctgcagct	gggggtgcag	950
gctgtggtct	accacggggg	ctatcttccc	tttcgggacc	ccaacagcga	1000
ggagaacagc	aacgatattg	ccctgggtcca	cctctccagt	cccctgcccc	1050
tcacagaata	catccagcct	gtgtgcctcc	cagctgccgg	ccaggccctg	1100
gtggatggca	agatctgtac	cgtgacgggc	tggggcaaca	cgcagtacta	1150
tggccaacag	gccgggggtac	tccaggaggc	tcgagtcccc	ataatcagca	1200
atgatgtctg	caatggcgct	gacttctatg	gaaaccagat	caagcccaag	1250
atgttctgtg	ctggctaccc	cgagggtggc	attgatgcct	gccagggcga	1300
cagcgggtgg	ccctttgtgt	gtgaggacag	catctctcgg	acgccacgtt	1350
ggcggctgtg	tggcattgtg	agttggggca	ctggctgtgc	cctggcccag	1400
aagccaggcg	tctacaccaa	agtcagtgac	ttccgggagt	ggatcttcca	1450
ggccataaag	actcactccg	aagccagcgg	catggtgacc	cagctctgac	1500
cggtggcttc	tcgctgcgca	gcctccaggg	cccgagggtga	tcccgggtgg	1550
gggatccacg	ctggggccgag	gatgggacgt	ttttcttctt	gggcccggtc	1600
cacagggtcca	aggacaccct	ccctccaggg	tcctctcttc	cacagtggcg	1650
ggcccactca	gccccgagac	cacccaacct	caccctcctg	acccccatgt	1700
aaatattggt	ctgctgtctg	ggactcctgt	ctaggtgccc	ctgatgatgg	1750
gatgctcttt	aaataataaa	gatgggttttg	att		1783

**WHAT IS CLAIMED IS:**

1. A method of diagnosing cancer in an individual, comprising the steps of:

5 (a) obtaining a biological sample from an individual; and

(b) detecting hepsin in said sample, wherein the presence of hepsin in said sample is indicative of the presence of cancer in said individual, whereas the absence of hepsin in said  
10 sample is indicative of the absence of cancer in said individual.

2. The method of claim 1, wherein said biological sample is selected from the group consisting of blood, urine, saliva,  
15 tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells.

3. The method of claim 1, wherein said detection of  
20 said hepsin is by means selected from the group consisting of Northern blot, Western blot, PCR, dot blot, ELIZA sandwich assay, radioimmunoassay, DNA array chips and flow cytometry.

4. The method of claim 1, wherein said cancer is selected from the group consisting of ovarian, breast, lung, colon,  
25 prostate and others in which hepsin is overexpressed.

5. A method for detecting malignant hyperplasia in a



biological sample, comprising the steps of:

(a) isolating mRNA from said sample; and

(b) detecting hepsin mRNA in said sample, wherein the presence of said hepsin mRNA in said sample is indicative of the presence of malignant hyperplasia, wherein the absence of said hepsin mRNA in said sample is indicative of the absence of malignant hyperplasia.

10           6.    The method of claim 5, further comprising the step of:

              comparing said hepsin mRNA to reference information, wherein said comparison provides a diagnosis of said malignant hyperplasia.

15

              7.    The method of claim 5 further comprising the step of:

              comparing said hepsin mRNA to reference information, wherein said comparison determines a treatment of said malignant hyperplasia.

20

              8.    The method of claim 5, wherein said detection of said hepsin mRNA is by PCR amplification.

25

              9.    The method of claim 8, wherein said PCR

amplification uses primers selected from the group consisting of SEQ ID No. 8 and SEQ ID No. 9.

10. The method of claim 5, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells.

11. A method for detecting malignant hyperplasia in a biological sample, comprising the steps of:

(a) isolating protein from said sample; and

(b) detecting hepsin protein in said sample, wherein the presence of said hepsin protein in said sample is indicative of the presence of malignant hyperplasia, wherein the absence of said hepsin protein in said sample is indicative of the absence of malignant hyperplasia.

12. The method of claim 11, further comprising the step of:

comparing said hepsin protein to reference information, wherein said comparison provides a diagnosis of said malignant hyperplasia.

13. The method of claim 11, further comprising the step of:

comparing said hepsin protein to reference information,

wherein said comparison determines a treatment of said malignant hyperplasia.

5                   14. The method of claim 11, wherein said detection is by immunoaffinity to an antibody, wherein said antibody is specific for hepsin.

10                   15. The method of claim 11, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells.

15                   16. A method of inhibiting expression of endogenous hepsin in a cell, comprising the step of:

                  introducing a vector into a cell, wherein said vector comprises a hepsin gene in opposite orientation operably linked to  
20 elements necessary for expression, wherein expression of said vector in said cell produces hepsin antisense mRNA, wherein said hepsin antisense mRNA hybridizes to endogenous hepsin mRNA, thereby inhibiting expression of endogenous hepsin in said cell.

25                   17. A method of inhibiting hepsin protein in a cell, comprising the step of:

                  introducing an antibody into a cell, wherein said

antibody is specific for a hepsin protein or a fragment thereof, wherein binding of said antibody to said hepsin protein inhibits said hepsin protein.

5

18. A method of targeted therapy to an individual, comprising the step of:

administering a compound to an individual, wherein said compound has a targeting moiety and a therapeutic moiety, wherein  
10 said targeting moiety is specific for hepsin.

19. The method of claim 18, wherein said targeting moiety is selected from the group consisting of an antibody specific  
15 for hepsin and a ligand or ligand binding domain that binds hepsin.

20. The method of claim 18, wherein said therapeutic moiety is selected from the group consisting of a radioisotope, a  
20 toxin, a chemotherapeutic agent, an immune stimulant and a cytotoxic agent.

21. The method of claim 18, wherein said individual  
25 suffers from ovarian cancer, lung cancer, prostate cancer, colon cancer and other cancers in which hepsin is overexpressed.

22. A method of vaccinating an individual against hepsin, comprising the step of:

inoculating an individual with a hepsin protein or fragment thereof, wherein said hepsin protein or fragment thereof  
5 lack hepsin protease activity, wherein said inoculation with said hepsin protein or fragment thereof elicits an immune response in said individual, thereby vaccinating said individual against hepsin.

10 23. The method of claim 22, wherein said individual has cancer, is suspected of having cancer or is at risk of getting cancer.

15 24. The method of claim 22, wherein said hepsin fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment.

20 25. The method of claim 24, wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

25 26. A method of producing immune-activated cells directed toward hepsin, comprising the steps of:

exposing dendritic cells to a hepsin protein or fragment



thereof, wherein said hepsin protein or fragment thereof lacks hepsin protease activity, wherein said exposure to said hepsin protein or fragment thereof activates said dendritic cells, thereby producing immune-activated cells directed toward hepsin.

5

27. The method of claim 26, wherein said immune-activated cells are selected from the group consisting of B-cells, T-cells and dendrites.

10

28. The method of claim 26, wherein said hepsin fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment.

15

29. The method of claim 28, wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

20

30. The method of claim 26, wherein said dendritic cells are isolated from an individual prior to said exposure, wherein said activated dendritic cells are reintroduced into said individual subsequent to said exposure.

25

31. The method of claim 30, wherein said individual has a cancer, is suspected of having a cancer or is at risk of getting a cancer.

5

32. An immunogenic composition, comprising an immunogenic fragment of a hepsin protein and an appropriate adjuvant.

10

33. The immunogenic composition of claim 32, wherein said hepsin fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment.

15

34. The immunogenic composition of claim 33, wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154.

20

35. An oligonucleotide having a sequence complementary to SEQ ID No.188.

25

36. A composition comprising the oligonucleotide of claim 35 and a physiologically acceptable carrier.

37. A method of treating a neoplastic state in an individual in need of such treatment, comprising the step of:

(a) administering to said individual an effective dose of the oligonucleotide of claim 35.


5

38. The method of claim 37, wherein said neoplastic state is selected from the group consisting of ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer and other  
10 cancers in which hepsin is overexpressed.

39. A method of screening for compounds that inhibit hepsin activity, comprising the steps of:

15 (a) contacting a sample with a compound, wherein said sample comprises hepsin protein; and

(b) assaying for hepsin protease activity, wherein a decrease in said hepsin protease activity in the presence of said compound relative to hepsin protease activity in the absence of said  
20 compound is indicative of a compound that inhibits hepsin activity.

**Fig. 1**




Fig. 2






Fig. 3




Fig. 4




Fig. 5




Fig. 6






Fig. 7





**Fig. 8**



**Fig. 9**






Fig. 10




Fig. 11A




Fig. 11B




Fig. 12A




Fig. 12B




Fig. 13A





Fig. 13B



**1.**                      ↓                      .15  
.  
.                      .  
**VVTAAHCVYDLYLPK**

**16** **.30**

SWTIQVGLVSLDNP

31 .45

**APSHLVEKIVYHSKY**

46 57

KPKRLGNDIAL

$\frac{1 \quad 6 \quad 10}{\text{HCVYDLYL}} \quad \dots \quad \frac{53 \quad 57}{\text{D}}$

site of 133 bp insert in TADG12

**Fig. 15**






Fig. 16A




Fig. 16B




Fig. 17A




Fig. 17B




Fig. 18A

### EXPRESSION OF PUMP 1




Fig. 18B




Fig. 19